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Over 90% of cervical cancer mortality occurs in low and middle income countries 
where early screening and management services are not widely available. Malawi 
has the highest cervical cancer incidence and mortality rates globally. Visual 
Inspection with Acetic acid (VIA) is the screening of choice, management is 
limited to chemotherapy and palliative care. 
 
This dissertation describes factors associated with provision of VIA during 
antenatal (ANC) and postpartum (PPC) care, and with acceptance of VIA during 
PPC clinics. We also describe the sociodemographic and health characteristics of 
women with labia minora elongation (LME) and examine their uptake of 
maternal health interventions. 
 
Methods 
The study sampled 529 women at a tertiary center in Malawi attending either 
ANC (pregnant 28+ weeks), or PPC clinic (postpartum 6 weeks). We conducted 
descriptive statistics followed by logistic regression models to determine the 
impact of sociodemographic, obstetric, clinical and relationship factors on rates 
of VIA offer and uptake. Then, we described the sociodemographic and health 
correlates of women with LME and explored their likelihood of being offered 




Women attending PPC clinics were more likely (AOR=5.19, p<0.001) to be 
offered VIA when compared to ANC.  
Women who had no school through primary (AOR=0.55, p=0.04), those with 
LME (AOR=2.04; p=0.003) and with abnormal vaginal exam signs (AOR=0.33; 
p=0.06) were more likely to be offered VIA compared to their counterparts. 
Women reporting high degree of sexual satisfaction were less likely to refuse VIA 
in PPC clinic (AOR=0.34, p=0.02).   
 
Women with LME were more likely to be illiterate or partially literate (12.4% v/s 
6.2%, p=0.03) and to have travelled more than 30 minutes to reach clinic (74.3% 
v/s 62.2% p=0.007). They were less likely to have undergone ultrasound exams 
(AOR=0.41, p=0.002) or to have had instrumentation (including cesarean 
section) during their most recent pregnancy or delivery (AOR=0.49, p=0.06). 
 
Conclusions 
Healthcare providers may be influenced by women’s sociodemographic, cultural 
and clinical characteristics while offering VIA screening during ANC/PPC clinics. 
Meanwhile, women’s sociodemographic background and personal attitudes seem 
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Chapter 1: Introduction 
 
1.1 Cervical cancer 
   
1.1.1 Etiology and pathophysiology 
The cervix is the lowest part of the uterus, connecting the uterine cavity to the 
vaginal canal. About 2-3 cm long, it consists of a uterine endocervix formed of 
mucus-secreting single-layer columnar epithelium and a vaginal ectocervix 
composed of nonkeratinizing stratified squamous epithelium. 1 The squamous 
cell layer consists of stratified, non-keratinizing glycogen-containing squamous 
epithelium that is 20-30 cells thick. In contrast, the columnar layer consists of 
tall, glandular, mucus-producing cells that are a single cell thick 2. The 
squamocolumnar junction (SCJ) where the two layers meet is involved in intense 
cervical metaplasia and microglandular hyperplasia as columnar epithelium is 
constantly replaced by squamous epithelium. This process is regulated by blood 
estrogen levels and by the effects of commensal bacterial flora. The SCJ is the site 
of origin for cervical cancer and its precursors. The constant cervical remodeling 
at the junction creates a ‘transformation zone’ between the old and new SC 
junctions, which is the site for more than 90% of all squamous cell carcinomas. 3,4 
 
Cervical cancer refers to a series of invasive carcinomatous changes arising in the 




cervical cancer are squamous cell (70-80% of all cases) and adenocarcinoma (10-
15% of all cases) 5,6. Although the pathophysiology of cervical cancer is poorly 
understood, current clinical consensus points to progressive epithelial changes 
following human papillomavirus (HPV) infection as a common etiology. 7,8 
Following HPV infection, viral particles pass through a breach in the cervical 
mucosa to attack the basal layer, resulting in ‘premalignant’ cervical 
intraepithelial neoplasia (CIN). The virus enters through a breach in the cervical 
epithelium and affects the basal layer. The viral DNA, which undergoes episomal 
replication at first, eventually expresses specific genes that encapsidate the viral 
genome to form progeny viruses that are now capable of replication 9. Fig 1 







Figure 1: HPV–mediated progression to cervical cancer.  
(Source: Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: 
unresolved issues. Nature Reviews Cancer 2007; 7(1): 11-22)  9 
The risk of developing cervical cancer is greatest in women aged 30-45 years. 6 At 
risk are women who show atypical cervical cytology (atypical squamous cell and 
atypical glandular cells) on examination, 10,11 who have been treated for CIN in 
the past 20 years 12,13 and who have persistent Human Papilloma Virus (HPV) 
infection. 8,14 Although the epidemiological association between cervical cancer 
and sexual activity was first described by Rigoni-Stern in 1842, 15 it took more 
than a century for researchers to establish HPV as the cause of cervical cancer.  
16,17 Researchers erroneously linked Human Simplex Virus (HSV), another 




newer technologies like viral typing, polymerase chain reaction and hybrid 
capture assays confirmed HPV as the etiological agent in the late 1980s. The link 
between HPV and cervical cancer screening has gained currency only recently, 
with the expansion of HPV testing and screening and large-scale immunization 
programs 19.  
 
Human Papilloma Virus (HPV) consists of a group of more than 160 identified 
species of DNA viruses that mostly cause infection of keratinocytes in the skin or 
mucus membranes in humans. Over 40 of them are known to be sexually 
transmitted, affecting primarily the anogenital region. 8 Castellsague et al. 
calculated the risk of developing adenocarcinoma associated with specific HPV 
types and found that the risk was highest for HPV 18 (OR = 410), followed by 
types 16 (OR = 164), 59 (OR = 163), and 33 (OR = 117). Other types strongly 
associated with adenocarcinoma include HPV types 35, 45, 51, and 58. 20 HPV 16 
and 18 are thought to have roughly the same efficacy in causing cervical 
carcinoma, 21 and are associated with over 72% of all cases in Africa. 22 Recent 
studies analyzing HPV-16 variants across the globe suggest that the papilloma 
virus may have co-existed with archaic hominins up to 40 million years ago, and 
may trace their current patterns of distribution among different populations to 
the movement of prehistoric homo sapiens and other hominid species out of 
Africa into Europe, Asia and the American continent. 23 HPV infection is often 
self-limiting, and only a small proportion of cases go on to breach the cervical 




resolve, especially in the absence of persistent HPV infection, or lower grade CIN 
(grade 1) that fails to progress. 7,8 The progression of CIN to cervical carcinoma 
can take more than 10 years 7. Fig 2 describes the epidemiological model of 
cervical cancer carcinogenesis. 
 
 
Figure 2: Epidemiological model of cervical cancer carcinogenesis.  
(Source: Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human 
papillomavirus and cervical cancer. The Lancet 2007; 370(9590): 890-907. 8 
 
For uninfected women, unprotected sexual intercourse with an infected partner is 
a major risk factor for contracting HPV, 14 as also an uncircumcised male sexual 
partner who has a history of multiple sexual partners. 24 Heavy smoking (</= 20 
cigarettes/ day) among women with HPV-16 infection increases the risk of 
developing invasive squamous cell carcinoma. 25-27 Two meta analyses of case 
control and cohort studies report a possible link between cervical cancer and long 
term contraceptive use (>/= 5 years), but the risk was found to reduce on 




pregnancies) is associated with an increased risk of developing cervical cancer 29, 
although evidence suggests this effect is only restricted to adenocarcinoma. 20 
Human Immunodeficiency Virus (HIV) positive women are also at increased risk 
of developing squamous intraepithelial lesions (SIL) following HPV infection 
compared to HIV-negative women, as well as have an increased risk of 
developing cervical cancer. The risk is greater in women with HIV and HPV co-
infection than either HIV or HPV infection alone. 30 
 
1.1.2 Epidemiology of cervical cancer morbidity and mortality 
Cervical cancer is the fourth most commonly diagnosed cancer and the fourth 
leading cause of cancer deaths among women worldwide, improving on its status 
as the second most lethal female cancer in 1975. 5,31,32 However, global 
distribution of cervical cancer deaths reveals dramatic differences between high-
income countries (HIC) and low- and middle-income countries (LMICs). 33,34 
Following an increasing trend over the past few decades, almost 90% of the 
estimated 311,000 deaths in 2018 occurred in LMICs, 31,32,35,36 especially 
countries in Sub Saharan Africa and South and Southeast Asia. 37,38 In addition, a 
greater number of cases of CIN progress to carcinoma in LMICs, age-
standardized prevalence rates of cervical cancer are greater than 30 per 100000 
(High-Risk) in Eastern, Southern, Middle and Western Africa but less than 7 per 
100000 (Low-Risk) in Australia/New Zealand, Western Asia, North Africa, and 





The reduction in cervical cancer prevalence and mortality in HICs has been 
largely due to the effect of regular screening and early management programs. 
35,39 In the past several decades, population-based cervical cytology screening 
programs in North America, Western Europe and Oceania have resulted in a 
reduction in nationwide mortality due to cervical cancer by up to 80%. 40 An 
analysis of five Nordic countries from 1955 to 1980 (Fig 3) conducted by the 
International Agency for Research on Cancer (IARC) revealed a dramatic 
decrease in cervical cancer mortality rates in countries like Iceland and Finland 
(84% and 50% respectively) that had instituted countrywide screening programs 
in the mid 1960s. Meanwhile, countries like Norway that offered screening 
coverage only in few counties saw a more modest drop (11%) in mortality rates. 40 
Even as new evidence suggests that previous estimates in HICs might have 
underestimated mortality, especially among minority populations, 41 current 
projections expect almost all cervical cancer deaths to occur in LMICs by 2030. 42 
Differential access to early screening and follow-up of suspected cases through 
efficient, nationwide programs has contributed greatly to the increasing disparity 
in prevalence and mortality rates of cervical cancer globally. 39,43 Multi-pronged 
strategies combining Human Papilloma Virus (HPV) vaccination with routine 
population and clinic-based screen-and-treat programs have been found to 
improve detection and management of pre-invasive lesions in LMICs, thereby 





Figure 3: Trends in cumulative cervical cancer mortality rates ( 0–74 years)  in five Nordic 
countries: 1965 – 1982.  
(Source: Saracci R, Wild C. International Agency for Research on Cancer: The First 50 
Years, 1965-2015; 2015.) 43 
 
1.1.3 Early detection, screening and management 
The big breakthrough in the approach to cervical cancer screening at the end of 
the previous century had been to recognize carcinoma as one of the many 
sequelae of HPV infection and to propose screening strategies that include a 
combination of tests to identify and stage lesions as well as isolate the virus. 46 
Cervical cancer is unique for the relatively early exposure to etiological agent 
(HPV), appearance of premalignant changes at affected site and long latency (and 
frequent resolution) before progression to carcinoma. 7 This makes it an ideal 
candidate for prevention programs involving routine screening of non-lethal 
sequelae and planned management of screening-positive women, in addition to 
detection of incident viral infection. Integration of routine cervical cancer 




efficient and cost-effective in reducing disease burden due to cervical cancer in 
Rwanda, in a program that is widely considered the first national program for 
cervical cancer prevention, care and control in Africa. 44 
 
The World Health Organization (WHO) recommends routine cervical cancer 
screening for all women over the age of 30 (younger if HIV positive). Women 
with a negative VIA/ pap tests are advised to repeat screening in 3-5 years (3 
years for HIV positive/high- endemic area/CIN1 or less women). HIV-negative 
women who are also HPV negative are advised to repeat HPV screening after a 
minimum interval of 5 years. 47 WHO recommends a ‘screen and treat’ approach 
to detect and manage CIN 1, 2 or 3 (CIN 3 and CIN 2 are often known together as 
CIN2+) in eligible women. Currently available screening tests include an HPV-
DNA test, visual inspection with acetic acid (VIA), and examination of cervical 
cytology (Papanicolou/Pap test). In resource-constrained settings, VIA is 
recommended over HPV-DNA testing or examination of cervical  
cytology. 47 For detected precancerous lesions, the treatment of choice is 
cryotherapy, if the entire lesion is visible, covering not more than 75% of the 
ectocervix, and the squamocolumnar junction is visible. 48,49 In cases where 
cryotherapy is contraindicated, loop electrosurgical procedure or large loop 
excision of the transformation zone (LLEEP/LLEETZ) is recommended. 47 WHO 
recommends cryotherapy and LEEP procedures over cold knife conization (CKC) 
wherever feasible (Strong recommendation, low quality evidence). 50 A 




(p=0.002) in prevalence of CIN2+ lesions at 6 months following VIA screening 
and cryotherapy (screen – and – treat strategy) compared to a delayed evaluation 
group. 45 The management strategy of choice for cervical cancer is surgery or 
radiotherapy depending on tumor stage and patient status, with adjuvant 
chemotherapy as indicated. 51  
 
An additional approach to screening and treatment programs involves 
vaccination against HPV infection, currently recommended for girls aged below 
15 years. 52 The past decade has seen significant advances in vaccine technology, 
and the latest iteration of the HPV vaccine in the US (trade name: Gardasil 9) 
protects against 90% of the viral strains that cause the disease in women. 53,54 The 
involvement of various governmental and non-governmental agencies has seen 
an expansion of immunization programs in developing countries over the past 
decade. 55 A demonstration project for HPV vaccine among girls aged 9-13 years 
was successfully completed in 2013 with support from  the global vaccine alliance 
(GAVI).  56,57 Vaccines, however, do not prevent older women or women already 
infected with HPV from developing cervical cancer. 
 
1.1.4 Visual Inspection with Acetic Acid (VIA) 
Visual Inspection with Acetic (VIA) is a process of naked-eye visualization 
(without magnification) of the uterine cervix after application of 3-5% acetic acid 
to screen for cervical abnormalities. The method was first described by Ottaviano 




developing world. 59-61 VIA relies on the interaction between 3-5% acetic acid and 
the squamous epithelial layer of the cervix, which is about 20-30 cells thick. 
 
Acetic acid causes a reversible coagulation of the nuclear proteins and 
cytokeratins present in cervical epithelium. When acetic acid is applied to the 
superficial layer of the cervix, it removes the surface mucus, but has little effect 
on the underlying cell layer as these are sparsely nucleated with profuse 
cytoplasm. In cases where intraepithelial neoplasia is absent (i.e., normal cervical 
histology), acetic acid is unable to penetrate the superficial squamous cell layer to 
reach the deep basal layer. Epithelial cells infected with certain types of HPV 
undergo morphological changes that result in relatively large nuclei with less 
cytoplasm. Acetic acid applied to this layer desiccates the cell contents, 
concentrating it and making it reflect light and appear opaque. 2,49 A positive test 
is characterized by well-defined, opaque acetowhite lesions in the transformation 
zone or if the external orifice or entire cervix turns acetowhite. Invasive cancer is 
suspected when a cervical growth turns acetowhite, or on observing bleeding of 
the cervical wall following acetic acid application. 2,62  
 
The immediately available results of VIA and its comparatively low costs of 
operation make it a suitable screening tool in low-resource settings. When 
coupled with cryotherapy, the screen-and-treat approach offers immediate 
evaluation and management for suspicious cervical lesions. 62-64 VIA requires 




successfully perform the test. 2,65 The 4-10 -day long competency-based training 
programs are suitable for community health workers, midwives, nurses, 
paramedical workers and doctors. VIA, however, suffers from all the drawbacks 
of a provider-dependent subjective test, and inconsistent provider competence 
often results in wide variability in test-positive rates, detection of high- grade CIN 
and low reproducibility of results. 62  
 
In a review of more than 50 studies looking at accuracy of VIA, a wide range of 
sensitivity (14 – 95%) and specificity (14 – 98%) was reported. 66 A subsequent 
meta-analysis of 11 studies described pooled estimates of 72%, 79%, 10% and 99% 
for sensitivity, specificity, PPV and NPV respectively. 67 Pooled estimates from a 
similar meta-analysis of 26 studies were 80%, 92%, 10% and 99% 68 respectively. 
The variability in sensitivity and specificity can be attributed to the subjective, 
provider-dependent nature of the test and the different endpoints measured in 
the studies. 69 VIA was found to have better sensitivity but lower specificity than 
conventional cytology methods; 66 69 additionally, specificity was seen to decrease 
significantly with HIV co-infection. 70 HPV-DNA testing consistently reported 
higher sensitivity and specificity than both VIA and conventional cytology. 45,71 In 
spite of these limitations, VIA is the best method for early detection of 
precancerous cervical lesions in pre-menopausal women in low-resource 





1.1.5 Factors influencing VIA uptake in low and middle income 
countries 
Before the widespread acceptability of VIA as a population-level screening 
strategy, cervical cancer detection in LMICs relied on liquid cytology-based 
testing to detect precancerous cases. The relatively resource-intensive nature of 
pap smears and testing made cervical cancer screening unattainable for a large 
segment of the population, a barrier that has reduced considerably with the 
introduction of VIA in LMICs. 60,72,75 Multiple factors including greater 
educational, economic and employment attainment, higher parity, HIV+ status, 
equitable domestic gender power relations, and awareness of cervical cancer and 
screening predict an increased likelihood of women accepting cervical screening. 
76,77 Misconceptions about the implications of screening, diagnosis and 
management options as well as cost, accessibility, quality of care and barriers to 
follow up negatively impact the rate of VIA uptake by eligible women. In the 
absence of appropriate treatment options like routine radiotherapy, women seem 
to be less motivated to access screening, even when it is available at the primary 
care level. 78,79 In general, awareness of cervical cancer and of screening methods 







1.2.1 General overview and demographic background 
Malawi is a landlocked country in South-Central Africa with a population of 18.62 
million (2017 census estimate). About 85% of its population is rural, and engaged 
in low-productivity subsistence farming. 81,82  Malawi’s (primarily agricultural) 
economy depends disproportionately on tobacco, maize and sugar cultivation, 
with tobacco alone accounting for almost 60% of the country’s exports. 83 
Classified as a low income country by the World Bank, Malawi has a GNI per 
capita of $1180 (2017, PPP current international $); 71% of the population earns 
less than $1.90 (2011 PPP) per day. 84 Among the world’s poorest non conflict-
affected countries, Malawi’s economy suffers from over-reliance on rain-fed 
agriculture, incomplete integration with the regional economy, out-migration of 
trained personnel and over-reliance on foreign aid to sustain a fragile 
macroeconomic stability. 81 Although real national gross domestic product has 
increased in recent years, the effects of unseasonal rains and extreme weather 
slowed economic growth most recently in 2015-16. 84 Globally, Malawi is one of 
the countries designated most vulnerable to the effects of climate change, 85 and 
repeated droughts in the North and floods in the South have hampered the 
economy’s efforts to grow and flourish. 86 
 
Formerly a British protectorate called Nyasaland, Malawi declared its 
independence in 1964. Following the formation of a Republic in 1966, Malawi 
was a single-party state ruled by the Malawi Congress Party (MCP) till 




led by President-for-life Dr Hastings Kamuzu Banda from 1964 – 1994; Dr 
Banda’s personal experiences as a physician in the US and the UK and autocratic 
style of functioning would come to have a lasting influence on many of the 
country’s policy decisions, especially regarding population control and family 
planning. 88 Through the 1980’s and 1990’s, Malawi had among the highest 
fertility rates in Eastern Africa (after Uganda, Burundi) and the second highest 
under-five mortality rate in Sub Saharan Africa. 89 The neo-malthusian family 
planning policies advocated by international agencies in Sub Saharan Africa in 
the 1970’s were resisted by the MCP government, which favored a more pro-
natalist approach. 88 Access to modern contraceptive methods was severely 
limited in the country till 1994, although access began to expand in the final years 
of MCP rule. Consequently, family sizes were high, and permanent sterilization 
was the method adopted to limit family size. 89 Malawi’s fertility rate was among 
the 10 highest in the world from 1975 to 1995 90. The universality of marriage and 
the higher rates of early marriage for girls (almost half of all women of 
reproductive age were married before the age of 18) 91 meant that age-specific 
fertility rates were high across all reproductive age groups during this time 
period. 92 Following the transition to a multi-party democracy, President Bakili 
Muluzi dramatically shifted the direction of Malawi’s population policy and 
declared population control as a legitimate strategy to development. 88  
 
The HIV/AIDS pandemic struck Malawi just as it was emerging from the legacy 




Adult mortality was high still 2005, before effective ARV distribution programs 
were established by the government. In 2008, the probability of dying between 
the ages of 15-60 was 43% for men and women; 65.1% of adult deaths were due to 
HIV/AIDS. 93 Malawi has a population structure today that is typical for LMICs 
with high birth and death rates (see fig 4). Over 60% (64%) of the population is 
under the age of 15 years, 18% under the age of 5 and only 3% above 65 years. 
Early childbearing is common, almost 30% of women aged 20-24 had had their 
first child before the age of 18. 91,94   
 
 
Figure 4: Malawi Population Pyramid, 2017.  
(Source: United Nations Population Division (2017). World Population Prospects: The 
2017 Revision. Geneva). 95 
 





































1.2.2 Women’s reproductive health in Malawi   
According to the results of the 2015-16 Demographic and Health Survey (DHS), 
total fertility rate (TFR) in Malawi is 4.4, down from 5.7 in 2010. 96,97 Malawi has 
among the highest maternal mortality ratios (MMR) in the world (439/100,000 
births). MMR in Malawi, which was already among the highest in the world in 
1980, 98 increased 1.81 times from 1990 to 2000, fueled at least partly by deaths 
due to HIV/AIDS. 99 High MMR in Malawi coexists with relatively high rates of 
skilled ANC coverage (51% of women attended at least four ANC visits, 95% at 
least one with a skilled provider) and institutional deliveries (91%). However, 
rates of skilled postpartum care (PPC) are low, only 42% of the population 
accessed PPC at a health center within the first 6 weeks after delivery. 91,100 
 
Following a transition from more pro-natalist policies to countrywide adoption of 
modern contraception in 1994, Malawi’s access to contraceptive services has been 
fairly widespread and rapid. The modern contraceptive prevalence rate rose from 
7% to 58% between 1992 and 2016, while the unmet need fell to 19% from a high 
of 37% in that same period. Between 2010 to 2016, the proportion of women aged 
15-49 years accessing modern contraceptive methods rose by 39%, with almost 
80% of those services accessed through the public sector. Injectables (22.5%), 
implants (9.0%) and female sterilization (8.3%) account for a majority of 





1.2.3 HIV epidemic in Malawi   
The HIV/AIDS pandemic that swept across Sub-Saharan Africa in the last decade 
of the 20th century affected Malawi’s health sector dramatically. Malawi’s 
HIV/AIDS prevalence rates ranked among the ten highest in the world in 2003. 
101 After peaking in 2001, deaths due to HIV/AIDS have recorded a steady 
decline, largely linked to nationwide distribution of anti-retroviral treatment 
(ART) through the public sector, beginning in 2005. 102,103 The government of 
Malawi mandated routine HIV testing of pregnant women in 2003, 104 and 
recommends provider-initiated testing and counselling services for all antenatal 
(ANC) and postpartum (PPC) clinic attendees. 105 However, HIV testing is widely 
viewed as a mandatory part of antenatal services by women in Malawi. 106 
Evidence indicates that the HIV/AIDS pandemic has had a permanent impact on 
fertility choices and migration patterns in Malawi, resulting in situational 
uncertainty and disrupted parenting patterns. 107,108   
 
1.2.4 Cervical cancer in Malawi 
Malawi has the highest age-standardized incidence rate of cervical cancer in the 
world (75.9/100,000 women/year), which accounts for over 78% of all diagnosed 
female cancers in the country. Diagnoses are predominantly of squamous cell 
carcinoma,  and almost 30% of all cancer deaths (45.9/100,000 women/year) 
among women aged 15-49 in Malawi is due to cervical cancer. 109 57. With an 
estimated 2879 deaths in 2018, Malawi has the highest cervical cancer mortality 





1.2.5 Cervical cancer prevention, screening and management 
Malawi instituted cervical cancer screening using VIA in 2004 as a pilot project 
in Mulanje district, which was subsequently expanded to cover the entire country. 
111 Malawi’s rates of pap smear testing for cervical cancer screening were among 
the lowest in the world (<5% in 2002-2003), 112 and the shift to VIA was seen as a 
way to expand access to screening while keeping costs down. As of January 2016, 
Malawi had 170 public VIA testing sites in the country, covering all the districts 
except Likoma Island. In 2015, 49,301 women were screened across the country, 
91.2% of whom were screened for the first time. VIA coverage (calculated as 80% 
of eligible women over 5 years) almost tripled from 9.3% to 26.5% in the years 
2011 – 2015. 111 Currently, screening is recommended every 5 years for women. 113 
Although protocols recommend regular screening and follow up, in case only 
one-time lifetime screening can be carried out, the ideal age group of 
beneficiaries is 30-39 years. 114 The World Bank recommended expanded VIA 
screen-and-treat as the most cost-effective screening intervention (USD/ DALYs 
saved) for Malawi in the National Health Sector Strategic Plan 2011-2016 
(NHSSP). 115 Building on the recommendations of the national reproductive 
health strategy, 116 routine cervical cancer screening was included in the NHSSP-2 
(2016-2020), the only reproductive cancer screening to be thus included. The 
NHSSP-2 recommends primary prevention strategies (i.e., HPV vaccination for 
girls ages 9-13, education about sexual risk reduction-related strategies, 




(detection and treatment of non-cancerous lesions using VIA/ cryotherapy/ 
LLEEP and HPV-DNA testing). Recognizing the contribution of cervical cancer to 
female morbidity and mortality, in 2017 the Ministry of Health in Malawi 
released the national cervical cancer control strategy  2016-2020 that aims to 
incorporate emerging strategies from existing efforts at cervical cancer 
prevention and control, institute universal HPV vaccine administration and 
promote integration of cervical cancer screening into HIV care. 105 Tertiary 
prevention, or diagnosis and treatment of invasive cancer involves advanced 
technology for timely treatment and where not possible, palliative care. 117  
 
A demonstration project for HPV vaccine among girls aged 9-13 years was 
successfully completed in Malawi in 2013 with support from GAVI. 118,119 From 
2013-2016, a school-based pilot HPV vaccination program 6 for girls aged 9-13 
years using quadrivalent Gardasil vaccine against HPV subtypes 18, 16, 11 was  
carried out in the districts of Rumphi and Zomba. Almost 90% of the school-
based cohort were comprehensively covered by the time of project completion. 120 
Following the institution of the Free Primary Education (FPE) policy in 1994, 
Malawi has enjoyed high rates of enrolment at the primary school level (6-13 
years), estimated at 94% of all girls aged 9-13 in 2016, although rates of 
recidivism and educational attainment seem to display concerning trends in 
recent years. 121 Nevertheless, the low rates of coverage for out-of-school girls 




attempts to reach these populations through other means. A country-wide rollout 
of HPV immunization is anticipated in 2019. 122  
 
The lack of radiotherapy services in Malawi hampers provision of appropriate 
care for cervical cancer patients, making treatment options largely limited to 
palliative         services. 123 Malawi also has a severe shortage of qualified 
oncologists – the country has only five oncologists and hematologists practicing 
full-time. 124 The paucity of appropriate management options for cervical cancer 
cases in Malawi underscore the importance of primary and secondary prevention 
strategies for cervical cancer control in Malawi. 125 
 
In spite of the impressive strides in recent years expanding cervical cancer 
screening, there are multiple barriers to access early screening and detection 
services for women in Malawi including cost, availability of services and lack of 
information regarding early screening and treatment options. 112,126 In a study 
assessing client satisfaction with VIA screening services in Malawi in 2013, 
Maseko et al. reported that knowledge of the screening test (VIA), confirmed 
appointment for screening, distance travelled to the health facility and waiting 
time were significant predictors of satisfaction 127. In a 2012 assessment in 13 
districts conducted through interviews with district co-ordinators and service 
providers, Munthali et al. identified lack of equipment, supplies and space, lack of 




staff shortage and absence of female providers as key system-level barriers to 
expanding screening access. 118 
 
1.2.6 Female genital modifications in Malawi: Labia Minora 
Elongation 
Labia minora elongation (LME) is a form of female genital modification practiced 
by multiple communities across different African countries including Malawi, 
Zimbabwe, Uganda, South Africa, Mozambique and the Democratic Republic of 
the Congo. 128-133 Along with steatopygia, (accumulation and deposition of large 
amounts of fat over the gluteus maximus), LME was initially reported in western 
scientific literature as a morphological characteristic present from birth among  
the khoi-san. 134,135 LME has subsequently been established as a long-standing 
cultural practice in multiple communities across South Eastern Africa, either 
alone or part of a series of puberty initiation rites for pre-pubescent and 
adolescent girls. 136 Manual stretching of the labia minora begins among girls 
aged 7-11 years within gender-segregated groups overseen by older adolescent 
girls. 137,138 Although regular labial stretching in girls is encouraged only up to 
puberty, continuation of elongation practices in adulthood may be accompanied 
by the use of specific herbal oils, unguents, powders or poultices. 129,136,138,139 
Although there is considerable heterogeneity among different communities, LME 
is commonly observed in matrilineal societies in Africa, and the practice is often 
guided and supervised by older female relatives. 140,141 WHO categorizes LME as a 




procedures to the female genitalia for non-medical purposes that are not included 
in categories 1-3 (this includes pricking, piercing, incising, scraping and 
cauterization of the genitalia) 142 
 
LME is practiced among different ethnic communities in Malawi, including the 
Chewa, the country’s largest ethnic group, and communities like Nyanja and 
Mang’anja in the South, although specific rituals and practices vary within 
communities and even within the same community living in different parts of the 
country. 143,144 LME in Malawi is associated with rural communities that have 
lower educational attainment and who traditionally practice it in the context of 
puberty initiation rituals for both boys and girls. 145 Like in other parts of Africa, 
the significance of LME in Malawi is linked to fertility and marriage and often 
described as an essential pre-requisite for women desirous of entering 
matrimony. 146-148 The practice of LME in early adolescence and adulthood is 
linked to its role in enhancing sexual pleasure for men and women, as a signifier 
of fecundity in women, and for enlarging the introitus to promote easier 
childbearing. 131,137,149-151  
 
In Malawi, girls aged 7-12 years are encouraged by older female relatives to 
perform manual elongation of the labia minora (“kukuna” in Chichewa) in 
gender-segregated ‘friend groups’ (“mansanje”). Upon attaining menarche, these 
girls undergo a series of puberty initiation rituals (known as chinamwali, 




period of instruction by an older woman from the community (anumkungwi) on 
subjects like personal etiquette, community practices and rituals. The ceremonies 
culminate in a peri-pubertal period of separation from the family in gender-
specific ‘camps’ known as chiputu, after which there is a public ceremony that 
welcomes new initiates into the community. Chinamwali rituals among some 
communities may include a period following the ceremony that is characterized 
by social acceptance of sexually risky or promiscuous behavior, in some cases, as 
a ritual act of intercourse with a shaman, referred to as the fisi, or hyena. 128,152 
Initiation rituals for boys often involve circumcision and a period of instruction 
and confinement culminating in a ceremonial event, which may be followed by a 
period of apparent social tolerance for sexually promiscuous behavior. 128,130,140,152  
 
Labial elongation is currently practiced by multiple tribes in Malawi with 
different degrees of adherence, and it is widely recognized that the introduction 
of Christianity over the last two centuries has irrevocably changed traditional 
practices and imperatives among various groups, for eg the introduction of 
chilangizo, a Christianized alternative to traditional chinamwali ceremonies in 
the Baptist Synod of Malawi. 144,153,154   
 





1.3.1 Health system overview 
Malawi has a three-tiered health system, and services are provided by a 
combination of public (55%), private for profit (PFP 20%), faith-based (Christian 
Health Association of Malawi CHAM 14%) and non-governmental (6%) 
organizations, with public and private employer organizations accounting for the 
remaining share. 155 There are four tertiary hospitals and 26 district hospitals in 
the country, each district hospital overseeing a population of 140,000 to 1.4 
million through 11-40 health centers located within its oversight area. The 
contribution of PFP facilities is mostly in provision of primary care, and there is 
widespread variation between urban and rural areas in both quality and coverage 
of services. 94  Rising disease burdens and disproportionate spending share 
continued to stretch an already overburdened public sector until 2013, when a 
wide-reaching corruption scandal in the health system (nicknamed “cashgate”) 
resulted in widespread donor withdrawal and extraordinary stress on public 
health financing systems. 156,157 Nevertheless, external sources continue to 
account for a disproportionate share of Malawi’s total health expenditure (74% in 
2016/17), although this funding is often targeted towards specific disease 
prevention programs. 158 The majority (84%) of funds for Malawi’s response to 
HIV/AIDS comes from international sources, however this share too, has shown 
a decreasing trend over recent years. 101,103 More recently, analysts warn that 
introduction of user-fees and “bypass fees” may have exacerbated inequity in 





1.3.2 Integration of reproductive, maternal, newborn, child and 
adolescent health services 
In 2008, WHO described integrated health services as a package of preventive 
and curative health interventions for a particular population group, often (but not 
always) distinguished by its stage in the life cycle, with the goal of ensuring 
continuity of care. Integration may be achieved across different delivery points 
and across multiple levels in the healthcare system, as well as through 
involvement of distinct sectors of the government in health policy formulation. 
Integration does not need to provide fully comprehensive care at the same site, 
but it does require healthcare providers to have skills to provide appropriate 
basic services and refer patients onward for necessary services not provided at 
the site. 160,161 Most integrated public health programs in LMICs tend to address 
communicable diseases, most notably HIV/AIDS, tuberculosis and malaria. 161-165 
However, successful integration of programs has proven challenging due to a 
variety of factors, including a lack of national integration policies, funding 
inequities and the tendency of programs to encourage enhanced collaboration 
absent shared responsibility. 166,167 Reproductive, maternal, newborn, adolescent 
and child health (RMNACH) services have been popular avenues for horizontal 
integration with other screening and diagnostic interventions, primarily because 
recipients are characterized by similar gender and background characteristics 
with specific health needs, much of it addressed through routine care and follow-





1.3.3 Integration of primary care and VIA services in Malawi 
Unlike HIV screening, which is well integrated into ANC screening in many 
settings, limited evidence exists concerning integrating VIA into other points of 
care where women are already at the facility. 168,169, In a 2018 systematic review of 
randomized clinical trial and non-randomized intervention studies that examine 
the effectiveness of integrating gestational and non- gestational non-
communicable disease (NCD) interventions with ANC among women and 
children in LMICs, Kikuchi et al. suggest that integration of VIA screening and 
RMNACH care has a clear positive impact on the uptake of screening services and 
identifying potential cervical cancer cases. The move from cervical cytology 
screening using pap smear to VIA has made integration more feasible and 
achievable for LMICs seeking to address low rates of cervical cancer diagnosis 
and prevention. 170 
 
Predictable barriers of cost, access and information about early detection and 
treatment continue to retard expansion of VIA coverage in Malawi. 112,126 To 
address system-level barriers to expanding screening access including longer 
commute and wait times, lack of supplies, space, equipment and gender-
appropriate staff (discussed previously), the Ministry of Health has sought to 
integrate  VIA screening with other points of primary care delivery. 118 127 
Malawi’s National Service Delivery Guidelines for Cervical Cancer Prevention 
recommends that VIA be offered by trained nurses and health workers at family 




Research (SRHR) policy advocates the integration of cervical cancer screening 
with primary care service provision. 171 109 However, evidence indicates that 
women accessing maternal healthcare, including family planning services, are not 
offered VIA screening routinely by healthcare providers, who may choose to 
selectively offer screening based on the clinic setting, patient characteristics and 
findings elicited during examination. 79,119  
 
1.4 Hypothesis and specific aims 
 
Antenatal and postnatal care represent an integral and unique point of contact 
with the health system for women in LMICs. The timing and nature of prenatal 
visits offers opportunities for systematic assessment and management of 
women’s reproductive health. Cervical cancer screening is a routine preventive 
health intervention that helps in early detection and management of the disease. 
Recent advancements in early screening and management of suspected 
precancerous cases have reduced the barriers to conducting successful screening 
programs in LMICs. Barriers to screening access for women may be provider-
driven and may be prompted by sociodemographic and cultural cues as well as 
clinical presentation during the visit. Access to VIA testing is also influenced by 
the women’s decisions regarding screening and its implications. The objective of 
this dissertation is to better understand the factors that influence women’s 
uptake of cervical cancer screening during routine ANC and PPC in Malawi and 




integrate VIA screening and maternal health care.  Data are drawn from a 
population of women seeking ANC and PPC care in a tertiary health facility in 
Blantyre, Malawi.   
 
AIM 1: To describe the clinical factors associated with women being offered VIA 
screening during ANC and PPC. 
 
AIM 2: To describe the sociodemographic and relationship factors associated 
with women’s acceptance of VIA screening during ANC and PPC. 
 
AIM 3: To describe the sociodemographic, health and wellness characteristics of 
women with labia minora elongation (LME) and examine provider treatment of 
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Chapter 2: Methods 
 
2.1 Study background and setting 
2.1.1 Maternal Morbidity Measurement Study 
Data for this study are drawn from a pilot study designed to test a maternal 
morbidity measurement tool in three countries (Jamaica, Malawi and Kenya) in 
2015-16. The objectives of the pilot were to quantify the morbidities women 
experience during and after childbirth and validate the tool. The pilot included 
approximately 1500 women across the three countries, thus 250 women from 
antenatal (ANC) and postpartum (PPC) care clinics in each country (500 total in 
each country). Women attending either ANC clinic and more than 28 weeks 
pregnant, or attending PPC clinic at six weeks postpartum were invited to be part 
of the pilot in each of the sites.  
  
2.1.2 Malawi study site – Queen Elizabeth Central Hospital, 
Blantyre 
Queen Elizabeth Central Hospital, Blantyre (QECH) was the sole study site of 
study in Malawi. QECH is a 1120-bed public hospital serving the healthcare needs 
of Blantyre, Malawi’s second-biggest city, and of Southern Malawi. It is a tertiary 
care center, one of four ‘Central Hospitals’ as well as the only teaching hospital in 
Malawi. 1 QECH caters to the primary care needs of the surrounding areas in 




Obstetrics and Gynecology at the hospital has had between three and six 
specialist physicians, two to three registrars and three to five intern medical 
doctors at different times over the past decade. There are between two and four 
nurse-midwives for each shift 2,3. The gynecology department manages women 
diagnosed with precancerous lesions or suspected cervical carcinoma. The 
primary methods of management are surgery, chemotherapy and referral to 
palliative care services. 4 QECH is expected to house Malawi’s first radiotherapy 
center for cancer care in 2019. 5 
 
2.1.3 Study protocol and sample 
The measurement tool consisted of three main data collection activities:  
 Questionnaire (face-to-face)  
 Physical exam including a pelvic exam 
 Medical record review.  
 
a) Study Flow 
Women accessing antenatal care or attending postpartum clinic at QECH were 
approached for enrolment in the study. Eligible women were briefed on the 
details of the study and administered informed consent. Women were free to 
refuse to participate in any of the data collection activities, and were free to 
discontinue the study at any time. Consenting participants were administered a 
questionnaire recording reports of clinical symptomatology and management, 




2.0, General Anxiety Disorder GAD-9 and Personal Health Questionnaire PHQ-
9), 6-8 and maternal history and current health status. 9 Data were collected using 
into a digital device (electronic tablet) and study investigators were either nurses 
or female medical physicians who had recently graduated from QECH. The goal 
of this questionnaire was to learn from the women’s perspective what their 
subjective experiences of the current or most recent pregnancy was.  
 
b) Physical exam 
The second part of the tool consisted of a physical exam (including vitals, general 
physical, breast and abdominal exam), followed by a pelvic inspection and 
internal exam. The physical exam was conducted by a clinical health professional 
in a separate location from the oral interview. The person doing the exam was 
asked to report on clinical findings and provide assessment of the overall well-
being of the women. The clinician was not privy to the results of the detailed 
questionnaire, and was not required to review any health records. VIA screening 
was part of the study protocol for the Malawi site so all women seeking care were 
expected to undergo screening as part of the internal exam. That said, if the 
clinician felt the woman was ‘ineligible’ for VIA, the clinician would not offer VIA 
and record the reason. Women who were considered eligible were asked if they 
wanted VIA, and could either accept or refuse.  These two decision points, the 
clinician’s and the woman’s, form the basis for the analyses for Aims 1 & 2 (see fig 
5). In case a positive VIA exam was recorded, the woman was referred to the 




assessment, the appropriate management strategy was discussed with the 
patient. Since QECH is a tertiary care center, the referral center is located within 
the same physical building.    
 
c) Record review 
The third part of the tool was a record review (the national health passport is 
used in Malawi) to assess the investigations and tests done prior to the current 
visit. The health passport in Malawi is a document that chronicles patient health 
records and health care visits. It is in the possession of the women themselves, 
and is required to be presented during public or private sector healthcare visits. 10 
Women without a health passport are required to buy a new one at the time of the 
visit.  
 
Study protocols and a majority of items in the questionnaire were the same for 
both ANC and PPC. In addition, both samples were simultaneously recruited at 
QECH during the course of the study. National screening guidelines in Malawi 
recommend regular VIA screening every 5 years for all women aged 30-49 years 
in the general population, aged 18-49 if at high risk of cervical abnormalities 
(including HIV+, early sexual debut, multiple partners, previous abnormal 
screening result). 11 The National Reproductive Health Service Delivery 
Guidelines (NRHSDG) recognize cervical squamous cell carcinoma as an AIDS 
defining illness, and requires yearly screening for women living with HIV, and for 




Screening is recommended for women who are currently pregnant, postpartum, 
or accessing post-abortion care, as well as women attending sexually transmitted 




Figure 5: VIA screening study in QECH, Blantyre 
 
2.2 Ethical considerations 
This study uses secondary data from the Malawi pilot study which was conducted 
by WHO in collaboration with QECH. Ethical approval was provided by WHO’s 
Research Ethics Review Committee (ERC). The study also cleared the ethics 
committees in each of the partner countries, including COMREC, (College of 
Medicine Research Support Center), the ethics and institutional review board at 





2.3 Dissertation overview 
This dissertation addresses three aims related to provision of screening, 
diagnostic and management interventions for women accessing maternal 
healthcare in QECH. A detailed description of the methods used for each aim is 
presented in the corresponding chapter of the dissertation.  
 
To address aims 1 and 2, we divided the clinical encounter into two component 
parts: whether VIA was offered by the clinician to eligible women, and if the 
screening test was accepted or refused by these women. For the first part, we 
considered all enrolled women who presented for antenatal or postpartum care at 
QECH during the study period (n=481, ANC=239, PPC=242). Among these 
women, we identified those who were offered VIA screening by the clinician 
during the physical exam, and analyzed the factors that might have contributed to 
this decision. On examining ANC and PPC sample separately, we decided to pool 
the samples as there were no significant differences in variables considered in the 
analysis between the antenatal and postpartum women.  
 
Among women offered VIA during ANC clinic, 92% refused screening, making 
the resulting sample too small for meaningful analysis. Thus, to address aim 2, 






To address aims 1 and 2, we first conducted descriptive statistics, followed by 
bivariate and multivariate logistic regression models to determine the impact of 
sociodemographic, obstetric, clinical and relationship factors on rates of VIA 
offering and uptake.  
 
To address aim 3, we considered all women who accessed ANC and PPC as part of 
the pilot study. Based on findings recorded during the pelvic exam (n=419, 
ANC=230, PPC=189), we identified women who had labia minora elongation 
(LME). We described the correlates of LME among women accessing maternal 
healthcare services and tested for differences in provision of screening, diagnostic 
and management interventions during the pregnancy, delivery and postpartum 
period. Specifically, we described sociodemographic, health and wellness 
variables for women with LME, the rates at which the women were offered 
ultrasound screening during ANC clinic, and the rates of cesarean section or 
other instrumentation during the most recent delivery. We also analyzed the 
rates at which VIA screening was offered for the entire sample. First, we 
conducted descriptive statistics of key covariates thought to be associated with 
LME, followed by a series of multivariate regression models, adjusting for key 
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Chapter 3: Factors Influencing Offer of Visual 
Inspection with Acetic Acid (VIA) Screening to 





Cervical cancer is the fourth leading cause of cancer mortality among women 
worldwide with almost 90% of the estimated 311,000 deaths in 2018 occurring in 
low and middle income countries (LMIC), 1-4 especially those in Sub Saharan 
Africa and South Asia. 5,6 Current projections expect almost all cervical cancer 
deaths to occur in less developed countries by 2030. 7 This is largely attributable 
to a ‘screening gap’ between developed and developing countries. Historically, 
early screening and follow-up of suspected cases through efficient, nationwide 
programs have contributed greatly to reducing mortality rates in developed 
countries. 8,9 Multi-pronged strategies combining Human Papilloma Virus (HPV) 
vaccination with routine population and  clinic-based screen-and-treat programs 
have been found to improve detection and management of pre-invasive lesions in 
developing country settings, thereby reducing overall risk of mortality. 10,11 
 
Between 80-90% of all cases of cervical cancer are either squamous cell or 




Frank carcinoma represents the final stages of a series of neoplastic changes 
within cervical tissue, almost always etiologically linked to HPV infection. 12,13 
Unprotected sexual intercourse with an infected (especially uncircumcised) 14 
partner represents the most important risk factor of contracting HPV for an 
uninfected woman. 15 Also, heavy smoking, long-term use of combined oral 
contraceptive pills, multiparity and presence of concomitant Sexually 
Transmitted Infections (STIs), including HIV are linked to increased risk of 
developing some forms of cervical cancer, both as independent risk factors as 
well as by accelerating disease progression in HPV-infected women. 16-21 Disease 
progression from incident infection to clinical manifestations takes an average of 
18.5 months, and frank carcinoma in the absence of appropriate management 
develops in about 10 years. 13,22 The slow progression of pre-cancerous lesions to 
frank carcinoma allows effective screening strategies, currently done either 
through examination and analysis of cervical epithelium to detect early dysplastic 
changes following HPV infection (Papanicolou (Pap) screening and Visual 
Inspection with Acetic Acid (VIA)), or through laboratory detection of HPV DNA 
correlated with clinical symptoms. 23  
 
3.1.1 Visual Inspection with Acetic Acid (VIA) Screening for Cervical 
Cancer 
Although HPV-DNA testing is widely regarded as the gold standard, in resource-
constrained settings, VIA is recommended for population-level screening of 




epithelial layer of the cervix to observe the resulting color changes, if any. A 
positive test is characterized by well-defined, opaque acetowhite lesions in the 
transformation zone or if the external orifice or entire cervix tns acetowhite. 
Invasive cancer is suspected when a cervical growth turns acetowhite, or on 
observing bleeding of the cervical wall following acetic acid application25,26. VIA 
is contraindicating for women allergic to acetic acid, those over 55 years, or who 
are currently experiencing heavy menstrual flow. 25 Multiple meta-analyses of 
studies on the efficacy of VIA conclude that the test tends to have better 
sensitivity but lower specificity when compared to conventional cytology-based 
methods of screening27-29. In addition, the subjective provider-dependent nature 
of the test may sometimes impact its reliability, in ways that may not be easily 
predictable. 30 In spite of these limitations, the immediate availability of results, 
low costs of operation, limited laboratory support and relative ease of training 
health workers to successfully evaluate and report VIA screening makes it ideal 
for developing country settings 26,31-33.  
 
Existing cervical cancer screening strategies in developing countries rely largely 
on provision of cytology or visual-inspection tests as part of routine primary care 
for women aged 30-50 years. 10,34 Unlike HIV counseling and testing which has 
been offered as part of standard maternal healthcare for over two decades, 
cervical cancer screening is not currently integrated into routine antenatal (ANC) 
or postpartum (PPC) care in developing countries, despite the clear link between 




The aim of this analysis is to understand uptake and potential barriers to VIA 
uptake in order to assess the feasibility of providing screening for cervical cancer 
during routine maternal healthcare in a developing country setting. By analyzing 
the factors associated with the clinician’s decision to offer or deny screening to a 
woman accessing maternal healthcare within a monitored setting, this research 
study offers an opportunity to understand some of the barriers to mainstreaming 
VIA during ANC and PPC care. 
 
3.2 Study Setting and Background 
 
3.2.1 Reproductive Health in Malawi 
Malawi is a land-locked country of 18.62 million (2017 census est) where more 
than 70% of the population earns less than $1.90 a day, 35 primarily employed in 
occupations dependent on rain-fed agriculture. 36 Malawi had among the highest 
fertility as well as under-5 mortality rates in Sub-Saharan Africa in the 1980s and 
90s. 37 Currently, the total fertility rate (TFR) is 4.4, down from 5.7 in 2010 and 
almost a third of women aged 20-24 have had their first child before the age of 
18. 38,39 The country also has among the highest estimated maternal mortality 
ratios (MMR) in the world (439/100,000 births), as well as relatively high rates 
of skilled ANC coverage (51% of women attended at least 4 ANC visits) and 
institutional deliveries (91%). 38,40 Malawi has the highest incidence of 
(predominantly squamous cell) cervical cancer in Eastern Africa (age 




diagnosed female cancers and almost 30% of all cancer deaths (age standardized 
45.9/100,000 women/year) among women aged 15-49 in the country.  41 42 With 
an estimated 2879 deaths in 2018, Malawi has the highest cervical cancer 
mortality rate in the world. 4,43 
 
3.2.2 Cervical Cancer Screening in Malawi 
Pap screening rates in Malawi have traditionally been low (<5% in 2005)44, but 
VIA screening was introduced in 2004 and expanded to cover almost the entire 
country by 2016. VIA coverage has tripled from 9.3% to 26.5% between 2011 to 
2015 in Malawi45. However, predictable barriers of cost, access and information 
about early detection and treatment continue to retard expansion of coverage. 
44,46 System-level barriers to expanding access in the literature include lack of 
supplies, space, equipment and gender-appropriate staff as well as long commute 
times to health facilities47 while awareness of the VIA test, waiting time, time to 
travel to the testing center and confirmed appointment for screening were seen to 
greatly influence client satisfaction for VIA. 48 Although the ministry of health 
recommends integration of cervical cancer screening with primary care service 
provision in the national Sexual and Reproductive Health Research (SRHR) 
policy, 41 evidence indicates that women accessing primary care services are not 
offered VIA screening routinely by clinicians - due to a variety of factors. 49,50 
Clinicians may choose to selectively offer screening based on the clinic setting, 
patient characteristics and clinical findings elicited during examination. Malawi’s 




that pregnant women may be safely screened by VIA, and suggests special 
attention be paid to women complaining of STI-related symptoms. 51  
 
The objective of this study is to assess the factors that influence clinicians’ 
decisions to offer VIA screening to women attending ANC/PPC care in a study 
setting where integration of these services was part of clinical protocol. Based on 
what is known about VIA integration as well as cervical cancer in Malawi, we 
hypothesized that clinicians decision to offer screening might be influenced by 
sociodemographic factors like the woman’s age, education, parity and marital 
status as well as clinical signs elicited during examination.  
         
3.3 Methods 
 
3.3.1 Study Design 
Data for this study are derived from the Maternal Morbidity Measurement Tool 
(MMMT) study, a cross-sectional research study that was conducted in Jamaica, 
Kenya and Malawi in 2015-16 to assess and quantify morbidities experienced by 
women in the antenatal and post-partum period. The MMMT study consisted of a 
questionnaire, physical exam and medical record review. The questionnaire was 
administered by trained investigators, who were clinicians trained for the survey. 
The questionnaire recorded women’s reports of clinical symptomatology and 
management as well as maternal history and current health status, including 




to assess female respondents’ subjective experiences of the current or most recent 
pregnancy.  
 
The physical exam consisted of a general obstetric exam followed by a pelvic 
inspection and internal exam. It was conducted in a separate location, recorded 
on paper and the supervising clinician was not privy to the information gathered 
in the questionnaire. The pelvic inspection and internal exam was offered based 
on clinical correlation assessed by the clinician. During the physical exam, 
clinicians (either nurses or Ob/Gyn physicians), were required to offer Visual 
Inspection with Acetic Acid (VIA) screening to all eligible candidates, irrespective 
of the woman’s screening history. In case VIA was not offered, clinicians were 
required to record the reason for ineligibility. Routine VIA screening is 
recommended as part of the national screening guidelines in Malawi. 
Participating women were free to refuse any part of the study or discontinue their 
participation at any time. Additional details of the study protocol are described by 
Say et al. 52 In all three sites, the MMMT was administered as part of routine ANC 
and PPC clinics. Ethical approval was provided by the WHO’s Research Ethics 
Review Committee (ERC) as well as by the RHR Research Project Panel (RP2), 
the external review body of the Department of Reproductive Health and Research 
(RHR). The study also cleared the appropriate ethics committees in each of the 
partner countries, including the College of Medicine Research Support Center 





3.3.2 Study Site 
In Malawi, the Queen Elizabeth Central Hospital, Blantyre (QECH) was the study 
site. QECH is a 1120-bed public hospital serving the healthcare needs of Blantyre, 
Malawi’s second-biggest city, and of Southern Malawi. It is a tertiary care center, 
one of four ‘Central Hospitals’ as well as the only teaching hospital in Malawi, 
catering to more than 45% of Malawi’s population living in the Southern region. 
56,57 Due to the often-unreliable public healthcare services in rural areas of 
Southern Malawi, QECH caters to the primary care needs of the surrounding 
areas in addition to provision of tertiary care in all specialties. The Department of 
Obstetrics and Gynecology at the hospital has had between 3 and 6 specialist 
physicians, two to three registrars and 3 to 5 intern medical doctors at different 
times over the past decade. There are between two and four nurse-midwives for 
each shift. 58,59 
 
3.3.3 Study Protocol 
Women attending ANC clinic and more than 28 weeks pregnant, or attending 
PPC clinic at 6 weeks postpartum were invited to be part of the study. Women 
who consented to participating in the survey were administered the 
questionnaire, physical exam and record review. All data was collected on site by 
study investigators using hand-held devices, collated and transmitted to a central 
data repository where it was entered and cleaned. As the data collected in the 
questionnaire was not immediately shared with the clinician, the reasoning 





3.3.4 Study Sample 
The final analytical sample of 409 women was drawn from a total of 529 
(ANC=252, PPC=277) who were approached to participate in the study. Of these 
women, 481 (ANC=239, PPC=242) consented to enroll in the study. 239 women 
attending ANC and 229 attending PPC clinic (total N= 468) were considered for 
VIA screening. Women currently menstruating (12) and post-hysterectomy (1) 
were excluded to create an eligible sample of 455 women (ANC=239, PPC=216). 
Of the 455 eligible women, 46 (ANC=37, PPC=9) were missing key co-variates 
that were part of the hypothesis and analysis.  The details of the sample selection 
are described in fig 6.  
 
Antenatal clinic 























Figure 6: Enrollment and selection into VIA testing, by clinic. 
 
Variables 
To better understand the factors associated with the clinician offering VIA to 
women, this analysis focuses on the characteristics of the women (both 
sociodemographic and clinical) that could be directly observed or elicited by the 
clinician, or which could be inferred from the brief obstetric history educed 
during the clinical encounter. 
 
Dependent Variable: The dependent variable for this study is whether the 
clinician offered VIA screening to the woman. It is important to note that study 









• Refused to 
participate = 35
Total sample 
considered for VIA  
(n=229)
• Refused pelvic 
exam = 13
Total sample 













VIA as part of the study.  However, if, during the postnatal exam it was evident 
that women had had a hysterectomy (n=1) or were menstruating (n=13) 
(contraindications for VIA), 25 those women were excluded. Based on the clinical 
reports, a dichotomous variable was generated to indicate whether women were 
offered or not offered VIA.  
 
Independent variables: Age, educational and marital status of the women were 
considered for analysis. Age was included as a continuous variable. Marital status 
was coded as a dichotomous variable (married or cohabiting versus single or 
divorced). Educational attainment was assessed using literacy status as well as 
through a binary variable (primary or less versus secondary or higher) and the 
variable that showed association with VIA offer was retained in the analytical 
model.  Women were characterized by whether they reported being currently 
employed at the time of the survey or not.    
 
Clinical variables: Labia Minora Elongation (LME) status (none versus present), 
abnormal vaginal exam signs (absent versus present) and first pregnancy 
(ongoing/ first delivery completed versus primigravida or recent first birth) were 
the clinical variables considered in the analysis. All three clinical variables are 
dichotomous. LME is a form of Female Genital Mutilation (FGM) that is seen in 
Malawi and is better described as a for of female genital modification. LME is 
classified by the WHO as FGM category 4. 60-62 The motivations, rituals and 




categories 1 through 3. In the absence of data collected that signifies religious or 
tribal status, LME recorded during physical examination may be a proxy 
indicator for ethnic background. 63 Abnormal vaginal exam signs included 
evidence of ulcers, lesions, excoriations or swelling in the external genitalia and 
the vagina as well as vaginal discharge seen upon examination. These may have 
influenced the clinician’s decision to offer or not to offer VIA screening, although 
none of these are contraindications for performing VIA, per se. 25 It is also 
possible that clinicians may treat women experiencing their first pregnancy or 
who have just had their first delivery differently from multiparous women.  
 
3.3.5 Analysis plan 
This study analyses the provision of cervical cancer screening to pregnant women 
over 28 weeks gestation attending ANC clinic and women up to 6 weeks 
postpartum attending PPC clinic. Consenting women who underwent the 
complete study including the physical exam, pelvic inspection and internal exam 
were considered for the analysis. The final sample analyzed all eligible women 
who had completed the survey, general physical and pelvic internal exam.  
 
To assess the similarity or differences between the antenatal and postpartum 
samples with the anticipation of conducting a pooled analysis, we first described 
key demographic characteristics of the sample potentially associated with 
attending ANC or PPC clinic. Next, we explored the relationship between each of 




clinical encounter - using t-tests and chi-square tests for significance. For 
analyses where individual cells had fewer than 10 observations, a Fischer’s exact 
test was used. We conducted bivariate logistic regression to assess the association 
of each independent variable with the outcome and then conducted multivariable 
logistic regression to explore factors that may have impacted the clinician’s 
decision to offer or not offer VIA. Finally, we conducted a descriptive analysis of 
the reasons clinicians reported for not offering VIA, stratified by visit type. All 
analyses were conducted using STATA ver14.1. 
 
3.4 Results 
A total of 481 women (ANC=239, PPC=242) were enrolled for the survey, of 
which 409 (ANC=230, PPC=179) are in the final analytic sample. Women 
excluded from this analysis include those who refused to undergo the pelvic exam 
(n=13), were ineligible due to menstruation or hysterectomy (n=13) or had 
incomplete or missing records for the variables of interest (n=46) considered in 
the analysis.  Results of the comparison between the ANC and PPC are shown in 
Table 1.   
  Overall, there were very few significant differences between the two samples.  A 
significantly greater proportion of the women in the ANC sample reported a past 
miscarriage compared to the PPC sample (23.9% vs. 17.3%, p=0.01).   
 
Table 1: Sociodemographic, clinical and obstetric characteristics of women in antenatal 
















     Mean  











Literacy    0.10 
    Illiterate/ Partially literate 7.4 (17) 12.2 (23) 9.6 (40)  
    Literate 92.6 (213) 87.8 (166) 90.5 (379)  
Education    0.35 
     Primary or less 26.5 (61) 30.7 (55) 28.4 (116)  
     Secondary or more 73.5 (169) 69.3 (124) 71.6 (293)  
Marital status    0.46 
     Single 7.0 (16) 8.9 (16) 7.8 (32)  
     Married/cohabiting 93.0 (214) 91.1 (163) 92.2 (377)  
Employment Status    0.07 
     Currently unemployed 53.5 (123) 62.6 (112) 57.5 (235)  
     Currently employed 46.5 (107) 37.4 (67) 42.5 (174)  
Time to reach clinic    0.59 
     <30 mins 30.4 (70) 33.0 (59) 31.5 (129)  
     >/= 30 mins 69.6 (160) 67.0 (120) 68.5 (280)  
Expressed fear of intimate 
partner violence 
   0.74 
     No 93.0 (214) 93.9 (168) 93.4 (382)  
     Yes 7.0 (16) 6.2 (11) 6.6 (27)  
Obstetric Characteristics 
Parity    0.29 
     Any previous births 66.5 (153) 61.5 (110) 64.3 (263)  
     First delivery 33.5 (77) 38.6 (69) 35.7 (146)  
History of miscarriage    0.01 
     No 76.1 (175) 82.7 (148) 79.0 (323)  
     Yes 23.9 (55) 17.3 (31) 21.03 (86)  
Clinical characteristics 
Abnormal vaginal exam signs a   0.20 
     No 94.8 (218) 97.8 (175) 96.1 (393)  
     Yes 5.2 (12) 2.2 (4) 3.9 (16)  
Labia Minora Elongation   0.32 




     Present 51.74å (119) 58.1 (104) 54.5 (223)  
a Due to small cell size, p-value determined with Fischer’s Exact test 
 
Most women (70.9%, n=290) attending ANC or PPC clinics were offered a VIA 
exam by the clinician; however, a significantly higher proportion of women 
attending PPC clinics were offered VIA when compared to women attending ANC 
clinics (87.7% versus 57.8%, p=0.001). Analysis of independent variables reveals 
that the proportion of women who were offered VIA did not vary by age, marital 
status or parity (Table 2). However, among women who were educated up to 
primary school, 80.2% were offered VIA as opposed to 67.2% of secondary school 
and higher (p=0.009). Slightly more than a third of 16 women who were 
diagnosed with abnormal signs on vaginal exam were offered VIA, as opposed to 
almost three quarters of the women who did not have any abnormal signs, and 
this difference was statistically significant. Among women who had undergone 
LME (greater than 55% of the sample), 78% were offered VIA, compared to 
62.4% among women who had not undergone LME (p=0.001).  
 
Table 2: Characteristics of women in antenatal (ANC) and postpartum (PPC) clinic visits, 
by clinician offering VIA (visual inspection with acetic acid) for cervical cancer 
Category VIA not 
offered  











Visit type    0.001 
     Antenatal care 42.2 (97) 57.8 (133) 100 (230)  
     Postpartum care 12.3 (22) 87.7 (157) 100.0 (179)  
Sociodemographic 
characteristics 
   




     Mean  







Literacy    0.38 
     Illiterate/ partially 
literate 
23.1 (9) 76.9 (30)   
     Literate 29.7 (110) 70.3 (260)   
Education    0.009 
     Primary or less 19.8 (23) 80.2 (93) 100.0 (116)  
     Secondary or more 32.8 (96) 67.2 (197) 100.0 (293)  
Marital status    0.49 
     Single 34.4 (11) 65.6 (21) 100.0 (32)  
     Married/cohabiting 28.7 (108) 71.4 (269) 100.0 (377)  
Clinical/ Obstetric 
characteristics 
    
Labia Minora 
Elongation (LME) 
   0.001 
     None 37.6 (70) 62.4 (116) 100.0 (183)  
     Any 22.0 (49) 78.0 (174) 100.0 (226)  
Abnormal vaginal 
exam signsa 
   0.008 
     No 27.7 (109) 72.3 (284) 100.0 (393)  
     Yes 62.5 (10) 37.5 (6) 100.0 (16)  
Parity    0.30 
     Any previous births 27.4 (72) 72.6 (191) 100.0 (263)  
     First pregnancy/ 
delivery 
32.2 (47) 67.8 (99) 100.0 (146)  
a Due to small cell size, p-value determined with Fischer’s Exact test 
 
Based on the significance levels and theoretically important variables, we 
conducted bivariate and multivariable logistic regression.  As there were no major 
changes between the bivariate and multivariable models, we focus on the results 
of the multivariable analysis (Table 3, column 3).  Women accessing PPC  were 
more than five times as likely (Adjusted Odds Ratio (AOR)=5.19; 95% CI 3.04 -
8.85, p<0.001) to be offered VIA when compared to women attending the ANC 
clinic. Women with a secondary school education or higher were only half as 




primary level (AOR=0.55, 95%CI 0.31-0.97, p=0.04). Women with LME were 
twice as likely to be offered VIA (AOR=2.04; 95% CI 1.28-3.26, p=0.003).   
Women with abnormal signs on vaginal exam were less likely to be offered VIA 
(AOR=0.33; 95%CI=0.11-1.04, p=0.06) compared to women with a normal 
vaginal exam.  
 
Table 3: Unadjusted and adjusted odds ratios of clinician’s decision to offer VIA 
(visual inspection with acetic acid) for cervical cancer, by the woman’s 









n = 409 
95% CI,  
p-value 
Visit Type     
     Antenatal care (ref) 1.00  1.00  
     Postpartum care 5.20 3.10-8.73 
p<0.001 
5.19 3.04 - 8.85 
p<0.001 
Sociodemographic Characteristics 
Age 1.00 0.96-1.03 
p=0.78 
1.00 0.95 - 1.05 
p=0.92 
Education     
     Primary or less (ref) 1.00  1.00  
     Secondary or more  0.51 0.30-0.85 
p=0.01 
0.55 0.31 - 0.97 
p=0.04 
Marital status     
     Single (ref) 1.00  1.00  
     Married/Cohabiting 1.30 0.61-2.80 
p=0.49 
1.15 0.45 – 2.94 
p=0.78 
Clinical & Obstetric Characteristics 
Labia Minora Elongation    
     None (ref) 1.00  1.oo  
     Any  2.14 1.39-3.31 
p=0.001 
2.04 1.28 – 3.25 
p=0.003 
Abnormal vaginal exam signs    
     No (ref) 1.00  1.00  





Parity     
     Any previous births 1.00  1.00  
     First pregnancy/delivery 0.79 0.51-1.23 
p=0.31 
0.79 0.43 - 1.46 
p=0.46 
aAdjusted for all variables appearing in the unadjusted column 
 
Although based on a relatively small sample, the reasons for not offering VIA 
screening to women attending the clinic are helpful to analyze the clinician’s 
stated motivations for offering or not offering screening. The top three reasons 
for not offering VIA among ANC clinic attendees were ‘not done/not indicated 
(69.1%)’, ‘VIA was done recently or will do later (7.2%)’ and ‘client is pregnant’ 
(4.1%).  In contrast, the top three reasons clinicians did not offer VIA to PPC 
clients were ‘client had had an episiotomy (22.7%)’, ‘VIA was done recently or 
scheduled for later (22.7%)’ and no supplies/ equipment (13.6%) (see Table 4).  
 
Table 4: Recorded reason (clinician) for not offering VIA (visual inspection with acetic 
acid) screening for cervical cancer, by visit type 
 
Stated reason ANC PPC Total 
Not done/ not indicated 69.1 (67) 4.5 (1) 57.1 (68) 
No supplies/ no equipment 2.1 (2) 13.6 (3) 4.2 (5) 
Cervicitis/ other abnormal 
vaginal discharge 
2.1 (2) 4.6 (1) 2.5 (3) 
Done recently/ scheduled for 
later 
7.2 (7) 22.7 (5) 10.1 (12) 
Episiotomy N/A 22.7 (5) 4.2 (5) 
Pregnant 4.1 (4) N/A 3.4 (4)  
Missing 15.5 (15) 31.8 (7) 18.5 (22) 
Total 100.0 (97) 100.00 (22) 100.0 (119) 





3.5 Discussion  
 
We studied the clinical encounters of 409 women accessing antenatal or 
postpartum care at the Queen Elizabeth Central Hospital in Blantyre to detect 
patterns in provision of VIA services. Although the integration of VIA with ANC 
and PPC care was an explicit part of the study protocol in Malawi, in practice 
women accessing maternal health services at QECH were only screened about 
70% of the time with a significantly higher rate of screening in PPC clinic (87.7% 
versus 57.8%).  
 
Women attending ANC clinics were roughly similar to women attending PPC 
clinics based on their sociodemographic background, clinical and obstetric 
history. However, ANC attendees were far more likely to have had a history of 
prior miscarriage as compared to PPC. This suggests that women attending ANC 
clinics have a riskier obstetric history than PPC attendees, possibly because 
women with history of adverse pregnancy events would be more likely to seek 
antenatal care from a tertiary center like QECH for subsequent pregnancies, as 
compared to postpartum clinic attendees.  
 
Woman’s education was associated with the decision to offer VIA, and secondary 
school or higher educated women were significantly less likely to be offered 




that clinicians had an idea of the woman’s level of education based on 
conversation and other social cues, but the clinicians did not have access to data 
collected on the woman’s educational status at the time of the encounter. Women 
who presented with abnormal signs during vaginal exam were also significantly 
less likely to be offered VIA screening. These included ulcers, swellings and 
abnormal vaginal discharge, none of which are contraindications for VIA. 25 This 
result is somewhat counter-intuitive as the presence of abnormal vaginal exam 
signs, while not definitive, might be indicative of incident STIs or increased risk 
of contracting them. 64 Excluding such women from screening could potentially 
miss out on a population at increased risk of developing HPV.  
 
We found that the odds of being offered VIA were significantly higher if the 
patient had undergone labia minora elongation as compared to women who had 
not. This result remained consistent even when adjusted for age, education, 
marital status, clinical exam signs and obstetric history. FGM in Malawi is 
different from more well-known and widely documented forms of female genital 
mutilation (categories 1-3) seen in Northern and Eastern parts of Africa and thus 
may be indicative of a very specific marker signifying tribe, regional identity or 
religion. 61 Women who have undergone the process of labial elongation (known 
as “chiputu” in Chichewa)65 and are sexually active would be seen as having 
participated in a series of puberty initiation ceremonies surrounding the 
“chinamwali” or ‘coming-out’ ritual. This attaches a specific set of assumptions to 




educational attainment and sexual behavior. 66 It is possible that clinicians 
considered the sample to be at greater risk for developing cervical cancer due to 
culturally-specific behaviors like early sexual debut and multiple sexual partners.  
 
An analysis of the stated reasons for not offering VIA reveals an overwhelming 
majority as “not done/ not indicated”, especially among ANC clinic attendees. 
This gives an indication of the challenges that a program designed to mainstream 
cervical cancer screening services with maternal health provision would 
potentially face. Clinicians also recorded ‘ongoing pregnancy’ and ‘recently 
screened’ as reasons for not offering VIA. It is possible that clinicians, being 
unsure of standard procedure for VIA screening during ANC care, preferred to err 
on the side of caution, particularly for pregnant women.  
 
The results of this analysis should be considered against some of the limitations 
of the study. First, the MMMT study used convenience sampling of women 
accessing ANC or PPC care during the study period at QECH, a tertiary teaching 
hospital. Malawi has both an early age of first pregnancy and a high total fertility 
rate, thus the sample of women accessing maternal health care is generally 
younger than the ideal age range for VIA screening (30-50 years). The study 
sample is probably not exactly representative of women who should be most 
urgently targeted for VIA screening. Additionally, the study was not designed to 
specifically consider barriers or facilitators to integrating VIA screening into 




example, we do not have data on clinician characteristics or data on the 
availability of supplies or equipment for VIA, nor do we have a direct observation 
of the encounters. Ideally, qualitative follow-up with clinicians could help provide 
the needed context and highlight barriers they experienced. Further work is 
needed before making recommendations on the feasibility of scaling up VIA 
screening in routine ANC and/or PPC care. 
 
Despite these limitations, there are number of important findings from this pilot 
study. First, while there was an explicit requirement in the protocol to offer all 
women VIA, clinicians seeing pregnant women offered VIA just over half the 
time. Furthermore, women exhibiting symptoms suggestive of STI were less 
likely to be offered screening, despite potentially at greater risk of developing 
cervical cancer. While we cannot know all of the reasons for clinicians not 
offering VIA consistently, the data suggest that attempts to integrate cervical 
cancer screening with maternal care in Malawi should be accompanied by 
comprehensive training of providers, including VIA eligibility requirements and 
risk factors for cervical cancer. Lastly, consistent adherence to clinical protocol by 
practicing clinicians cannot always be pre-supposed, even under closely 
monitored study settings. The variation in the rate at which women are offered 
services while accessing routine maternal care at a tertiary health center 
underscores the challenges of integrating opportunistic screening programs with 
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Chapter 4:  Factors Influencing Visual Inspection 
with Acetic Acid (VIA) Testing Uptake Among 
Postpartum Clinic Attendees In Blantyre, Malawi 
 
4.1 Introduction  
 
In 2008, the World Health Organization (WHO) defined successful integrated 
programs as those in which healthcare service delivery is organized so that 
patients can access “the care they need, when they need it, in ways that are user-
friendly, achieve the desired results and provide value for money”. Integration 
does not need to provide fully comprehensive care at the same site, but it does 
require healthcare providers to have skills to provide appropriate basic services 
and refer patients onward for necessary services not provided at the site. 1,2 Most 
integrated public health programs in low- and middle- income countries (LMICs) 
tend to address communicable diseases, most notably HIV/AIDS, tuberculosis 
and malaria. 2-6 Reproductive, maternal, newborn, child and adolescent health 
(RMNCAH) services have been popular avenues for horizontal integration with 
other screening and diagnostic interventions. RMNCAH services typically 
provide care to a specific population subgroup characterized by specific gender 
and age distribution who have different health status. 7,8,2,9 The intuitive rationale 
favoring integration assumes greater significance in LMICs with limited health 




integrated programs has proven challenging due to a variety of factors. These 
include a lack of national integration policies, funding inequities, increased 
burden on providers and the tendency of programs to encourage enhanced 
collaboration absent shared responsibility. 10,11 In recent years, amid growing 
recognition of the contribution of non-communicable diseases (NCDs) to the 
mortality burden in middle-income countries, 12 integration of NCD prevention 
and control within routine programmatic areas like RMNCAH has been widely 
promoted. 3  
 
4.1.1 Cervical cancer screening in LMICs 
Cervical cancer is largely attributable to clinical sequelae following human 
papillomavirus (HPV) infection, especially HPV types 16 and 18. 13 It is the fourth 
most commonly diagnosed cancer and the fourth leading cause of cancer deaths 
among women worldwide. 14-16 Over 85% of cervical cancer deaths occur in 
LMICs located in sub-Saharan Africa and South Asia, 15,17-20 where inadequate 
screening and inequitable access to treatment for women has resulted in a 
disproportionately high mortality burden. 21-23 Meanwhile, population-based 
cervical cytology screening programs and timely management of suspected 
precancerous lesions has contributed significantly to the reduction in disease 
burden in high-income countries in recent decades. 24-26 Programs providing 
routine screening, early detection and appropriate management of premalignant 
lesions in eligible women are central to efforts to reduce cervical cancer incidence 




followed by emergent treatment with cryotherapy is seen as the most effective 
and efficient method to manage premalignant lesions in poorer countries, 
preventing disease progression to malignancy needing surgical intervention – 
which is often inaccessible and expensive. 29 30,31 Despite these advances, 
screening rates in LMICs remain as low as 4.1%. 32 The scarcity of prevention 
services within the healthcare system and unresponsive policies coupled with 
multiple barriers to accessing screening results in under-screened populations 
that are nevertheless at high risk of developing cervical cancer. 33  
 
4.1.2 Factors influencing uptake of cervical cancer screening in 
LMICs 
Before the widespread acceptability of VIA as a population-level screening 
strategy, cervical cancer detection in LMICs relied on liquid cytology-based 
testing to detect precancerous cases. The relatively resource-intensive nature of 
pap smears and testing made cervical cancer screening unattainable for a large 
segment of the population, a barrier that has reduced considerably with the 
introduction of VIA in LMICs. 29,34,35 Sociodemographic factors including greater 
educational, economic and employment attainment, higher parity, HIV+ status, 
equitable domestic gender power relations, and awareness of cervical cancer and 
screening predict an increased likelihood of women accepting cervical screening. 
36,37 Personal factors like misconceptions about the implications of screening, 
diagnosis and management options are seen to influence screening uptake by 




methods exert greatest influence on women’s decision to access testing, along 
with service delivery issues like cost, accessibility, quality of care and barriers to 
follow up. 39 Mindful of the link between sexually transmitted infections and 
cervical cancer, women are often reluctant to undergo an internal exam for 
screening, especially when a positive diagnosis offers few avenues for timely and 
appropriate management. 40 Additional factors like dyspareunia and a history of 
sexual abuse may contribute to a general discomfort with internal exams in the 
clinical setting. 41,42  
 
Malawi has the highest cervical cancer incidence in Eastern Africa, accounting for 
the highest proportion of cancer deaths among women in the country. 43-45 The 
national cervical cancer screening policy targets testing 80% of all eligible women 
(aged 30-45 years, comprising 6.74% of the total population) within 5 years. 
Coverage rates have shown an encouraging increase from 9.3% to 26.5% from 
2011-2015, but far greater efforts are needed to ensure effective diagnosis and 
management of affected women. Malawi’s screening program continues to face 
issues of cost, availability, and lack of political support for aggressive expansion 
of early screening and treatment options. 32,46-48. Furthermore, case series studies 
at tertiary centers indicate an inordinate amount of delay between the onset of 
symptoms and screening, as well as between positive VIA test and follow up. 49 In 
Malawi, awareness regarding testing, greater accessibility of health facilities and 
shorter waiting times were linked to greater acceptance of cervical cancer 





In addition, perceived inadequacies of the health system leading to irregular care 
and absence of female providers were seen as barriers to access. 52 Very few trials 
have rigorously tested the efficacy of integrating cervical cancer screening with 
routine RMNCAH care. Successfully evaluated programs report screening trends 
that exceeded official targets, while test positivity rates remained comparable to 
previous districtwide numbers. 53 Rates of emergent treatment and follow-up also 
showed a steady increase, with constraints on the program’s success imposed 
largely by logistical inadequacies at the testing site. 54Our paper analyzes the 
factors influencing uptake of integrated VIA screening for cervical cancer among 
women attending postpartum clinic at a tertiary public healthcare facility in 




4.2.1 Study Design 
This paper studies women accessing postpartum care (PPC) at a tertiary hospital 
in urban Malawi. Data for the study is derived from the WHO Maternal 
Morbidity Measurement Study (MMMS) study, a cross-sectional research study 
conducted in 2015-16 to assess and quantify morbidities experienced by women 
in the antenatal and post-partum period. The MMMS study consisted of a 
questionnaire, physical exam and medical record review and was administered to 




questionnaire recorded women’s sociodemographic background, relationship 
details, obstetric history, clinical symptoms and management, current health 
status, functional assessment and mental health screening 55-59 This was followed 
by a general obstetric exam, pelvic inspection and internal exam by the assigned 
clinician (either nurses or Ob/Gyn physicians). During the exam, eligible women 
were offered Visual Inspection with Acetic Acid (VIA) screening, and reasons for 
ineligibility (if any) were recorded. Integration of VIA screening with primary 
care is one of the stated objectives of Malawi’s National Reproductive and Sexual 
Health and is recommended as part of the national screening guidelines in 
Malawi. The record review assessed the national health passport carried by the 
women that detailed their past medical and obstetric history. All data was 
collected on site by study investigators using hand-held devices, collated and 
transmitted to a central data repository where it was entered and cleaned. Ethical 
approval was provided by the WHO’s Research Ethics Review Committee (ERC) 
in addition to COMREC, (College of Medicine Research Support Center), the 
ethics and institutional review board at the College of Medicine, Blantyre, 
Malawi. 
 
4.2.2 Study Site 
The study was conducted at the Queen Elizabeth Central Hospital (QECH), a 
1120-bed public hospital in Blantyre, Malawi’s second-biggest city. QECH is a 
tertiary care center, one of four central hospitals as well as the only teaching 




districts of Southern Malawi in addition to the city of Blantyre and its suburbs. 
The Department of Obstetrics and Gynecology at QECH has between three to six 
specialist physicians, two to three registrars and three to five intern medical 
doctors, as well as up to four nurse-midwives for each shift 61,62. 
 
4.2.3 Study Sample 
For this analysis, we focus on women receiving PPC at six weeks postpartum, who 
were invited to be part of the study. Participating women were screened to 
determine eligibility and women who consented to the study were administered 
the questionnaire, physical exam and record review. A total of 277 women 
attending PPC clinic were approached to participate in the study. Of these 
women, 242 women consented to enroll in the study, of whom 229 were 
evaluated by the clinician during the physical exam. A total of 194 eligible women 
were offered VIA screening by the clinician. 
 
4.3 Variables 
The dependent variable for this study is the woman’s decision to accept or refuse 
VIA after being offered screening by the clinician. The independent variables, 
grouped as sociodemographic, relationship, self-reported health and clinic visit 





4.3.1 Sociodemographic characteristics 
Age (years), marital status (married or cohabiting versus single or divorced), 
educational attainment (primary or less than primary, secondary school and 
higher), and employment status were explored. Education was assessed using 
both literacy and actual years of schooling, and the variable that was significantly 
associated was retained in the final model. Parity was coded into three categories 
(1, 2-4, 5 or more)  
 
4.3.2 Relationship characteristics  
Marital status, satisfaction with current sex life and fear of partner were 
evaluated as relationship factors that could possibly influence the woman’s 
acceptance of screening. Almost 90% of first births in Malawi occur within 
marriage, and a woman’s age at first childbearing and fertility are higher when 
women’s education is higher. 63 64 Satisfaction with sex life is a proxy indicator for 
relationship quality. Similarly, women reporting fear of their current partners 
might be reluctant to accept screening, even though they might be at higher risk 
of contracting HPV infection. 65 
 
4.3.3 Self-reported health 
Women were asked to assess their overall health status on a scale of five, from 
very good to very poor.  With limited variation in scores, we created a binary 
variable (very good and good versus neutral, poor, and very poor).  In addition, 




questionnaires were administered to assess mental health status. 57,58 The GAD-7 
scores anxiety disorder based on the response to seven questions with response 
categories ranging from not at all (0) to nearly every day (3). The PHQ-9 is used 
to measure depressive symptoms. Each of the nine items are scored between 0 
(not at all) to 3 (nearly every day). As the incidence of clinical depression and 
anxiety was too low to be meaningfully considered in the analysis, we identified 
women who reported at least one symptom on the PHQ9 scale for depression and 
on the GAD7 scale for anxiety, and used this variable for analysis. To assess 
mental health status, women who reported experiencing any one of the 
symptoms of anxiety or depression were compared to women who scored nil on 
the test.    
 
4.3.4 Clinic visit characteristics 
Distance travelled by women to reach the health center might have an impact on 
the decision to accept or refuse screening. 50 The extra time commitment involved 
in undergoing opportunistic VIA screening during a scheduled PPC visit might 
influence the woman’s choice to accept or refuse the test.  
 
4.4 Analysis plan 
First, we described the sample of women who accessed postpartum care at 
QECH, Blantyre and among those, women who were offered VIA screening as 
part of routine clinical care. Next, we explored the relationship between each of 




among women who were offered VIA using t-tests and chi-square for significance 
testing.  Following this, we conducted bivariate and multivariate logistic 
regression analysis assessing the odds of accepting VIA in relation to women’s 




4.5.1 Characteristics of the study population 
Table 5 describes the background characteristics of the full sample of 242 women 
who were surveyed while accessing postnatal care, and the subset of 194 women 
who were offered VIA screening (analytical sample) during the physical exam 
(Table 5).  Of the 229 women who had a physical exam, 35 were not offered VIA, 
and the clinician’s reasons for not offering are described in Table 6. Overall the 
characteristics of the women in the analytic sample were similar to the full 
sample enrolled in the study.   
 
4.5.2 Sociodemographic, relationship and self-reported health 
The mean age of the sample of 194 women offered VIA was 26.4 years, (range 15-
50 years). Over two-thirds of the women were educated up to secondary school or 
higher, and 37.6% were currently employed at the time of the study (Table 5). 
More than a third of the women were attending postpartum clinic following their 
first delivery, and about 10% had had five or more pregnancies carried to term. 




similar proportion (88.7%) reported currently enjoying good or very good health. 
Less than 10% of our sample (6.7%) reported being afraid of their partner either 
some or all of the time, and a vast majority (80.4%) reported being currently 
satisfied with their sex life. An overwhelming majority of women reported no 
symptoms suggestive of anxiety or depression.  
 
4.5.3 Visit characteristics  
About one-third of the women travelled less than 30 minutes to reach the clinic, 
and two-thirds took longer (Table 5). The women were all residents of different 
administrative wards in Blantyre city, but their commute times may have been 
influenced both by proximity to the hospital as well as availability of 
transportation. Almost two-thirds of the women attended the postnatal clinic to 
access contraceptive services.  
 
Table 5: Sociodemographic, Relationship, Self-Reported Health, and Visit Characteristics 












Sociodemographic characteristics   
Age years   
Mean 26.4  26.4  
Range 15-50 15-50 
Literacy, % (n)   
Illiterate/ partially literate 12.4 (30) 13.4 (64) 




Education   
Primary school or less 28.9 (70) 33.0 (97) 
Secondary school and higher 71.1 (172) 67.0 (33) 
Employment Status, % (n)   
Unemployed 60.3 (146) 62.4(121) 
Currently employed 39.7 (96) 37.6(73) 
Number of pregnancies carried to term, % (n)   
1 38.8 (94) 36.1 (70) 
2-4 52.1 (126) 54.6 (106) 
5 or more 9.1 (22) 9.3 (18) 
Relationship characteristics   
Marital status, % (n)   
Married/ cohabiting 89.3 (216) 89.2 (173) 
Single/ separated /divorced 10.7 (26) 10.8 (21) 
Fear of partner, % (n)   
Never 93.0 (225) 93.3 (181) 
At least some of the time 7.0 (17) 6.7 (13) 
Satisfied with sex life since delivery, % (n)   
No  19.4 (47) 19.6 (38) 
Yes 80.6 (195) 80.4 (156) 
Self-reported health   
Self-reported health, % (n)   
Good/ very good 88.4 (214) 88.7 (172) 
Neutral, poor, very poor 11.6 (28) 11.3 (22) 
Self-reported depressive symptoms PHQ9    
No symptoms reported 84.3 (204) 87.6 (170) 
At least one symptom reported 15.7 (38) 12.4 (24) 
Self-reported anxiety symptoms GAD7    
No symptoms reported 73.1 (177) 75.3 (146) 
At least one symptom reported 26.9 (65) 24.7 (48) 
Visit Characteristics   
Time taken to reach health center, % (n)   
<30 mins 36.4 (88) 33.5 (65) 
>/= 30 mins 63.6 (154) 66.5 (129) 
Cesarean section delivery, % (n)   
No 78.1 (189) 79.9 (155) 
Yes 21.9 (53) 20.1 (39) 
Family Planning Visit   
No 35.5 (86) 33.5 (65) 







Table 6: Stated reasons for not offering VIA screening to women who attended 
Post-Partum clinic 
 
Reason for not offering VIA Frequency (%, n) 
Menstruating 28.6 (10) 
Done recently / scheduled for gyn clinic 14.3 (5) 
Recent episiotomy 14.3 (5) 
No supplies 14.3 (3) 
Hysterectomy 8.6 (3) 
VIA not done  0.3 (1) 
Cervicitis 0.3 (1) 
Missing/ reason not recorded 20.0 (7) 
Total 35 
 
4.5.4 Factors related to women’s acceptance or refusal of VIA 
screening during the postpartum visit 
Table 7 shows the characteristics of the women who were offered screening, by 
their acceptance or refusal of VIA testing status. A total of 194 women were 
offered VIA screening, of which 40 women (20.6%) refused screening. There 
were no significant differences in terms of mean age, literacy status or education.   
On analyzing factors that might be related to the women’s decision to accept or 
refuse VIA, we found a significant association with relationship factors, especially 
marital status and reported satisfaction with sex life. Women who refused 
screening were less likely to be married (80% vs. 92%, p=0.04) and less likely to 
be satisfied with their sex lives (68% vs. 84% p=0.02). They tended to be more 
likely to report fear of partner (13% vs. 5% p=0.10). None of the other factors 
were significantly associated with the woman’s acceptance or refusal of screening.  
 
 
Table 7: Women Accepting or Refusing Visual Inspection with Acetic Acid (VIA) 



















Sociodemographic     
Age, years    p=0.15 
Mean 26.8  25.1  26.4   
Range 15-50  16-46  15-50   
Literacy, % (n)    p=0.39 
Illiterate/ partially literate 12.3 (19) 17.5 (7) 13.4 (26)  
Literate 87.7 (135) 82.5 (33) 86.6 (168)  
Education, % (n)    p=0.65 
Primary school or less 33.8 (52) 30.0 (12) 33.0 (64)  
Secondary school or more 66.2 (102) 70.0 (28) 67.0 (130)  
Relationship     
Marital status, % (n)    p=0.04 
Married/ cohabiting 91.6 (141) 80.0 (32) 89.2 (173)  
Single/ separated/ 
divorced 
8.4 (13) 20.0 (8) 10.8 (21)  
Fear of partnera , % (n)    p=0.10 
Never 94.8 (146) 87.5 (35) 93.3 (181)  
At least some of the time 5.2 (8) 12.5 (5) 6.7 (13)  
Satisfied with sex life 
since delivery,  % (n) 
    
p=0.02 
No  16.2 (25) 32.5 (13) 19.6 (38)  
Yes 83.8 (129) 67.5 (27) 80.4 (156)  
Self-reported health,  
% (n) 
    
Self-reported health     p=0.17 
Good/ very good 90.3 (139) 82.5 (33) 88.7 (172)  




    
p=0.98 
No symptoms reported 87.7 (135) 87.5 (35) 87.6 (170)  
At least one symptom 12.3 (19) 12.5 (5) 12.4 (24)  
Self-reported anxiety 
symptoms GAD7  
   P=0.20 
No symptoms reported 77.3 (119) 67.5 (27) 75.3 (146)  
At least one symptom 22.7 (35) 32.5 (13) 24.7 (48)  
Visit Characteristics     
Time taken to reach 
health center, % (n)  




<30 mins 31.8 (49) 40.0 (16) 33.5 (65)  
>/= 30 mins 68.2 (105) 60.0 (24) 66.5 (129)  
Family Planning Visit, 
% (n) 
   p=0.88 
No 33.8 (52) 32.5 (13) 33.5 (65)  
Yes 66.2 (102) 67.5 (27) 66.5 (129)  
a Fischer’s test used due to small cell size 
 
Table 8 displays the results of bivariate and multivariate logistic regression 
analysis of the factors influencing women’s decision to refuse VIA screening 
during the postpartum visit. We selected those variables that were theoretically 
important and/or significantly associated with the outcome (based on Table 7).  
 
Following trends observed in Table 7, marital status and reported satisfaction 
with sex life were significantly associated with the decision to refuse VIA 
screening. In the multivariate model, we found some shifts in statistical 
significance but no shift in the direction of the associations. Older women were 
significantly less likely to refuse VIA as (AOR=0.93, p=0.05). Women who 
reported satisfaction with their sex lives were also significantly less likely to 
refuse screening (AOR=0.34, p=0.02). 
 
 
Table 8: Unadjusted and adjusted odds ratio for women’s decision to refuse VIA 
screening during postpartum visit 
 
 Unadjusted  
Odds Ratios  
(n=194) 
95% CI  
(p-value) 
Adjusted  













(Secondary or more 













    




Fear of Partner 
reported 








Self-Reported Health     
Overall health is 
good/very good (vs 
neutral/poor) 




1 Adjusted for all variables in the unadjusted column 
 
4.6 Discussion 
This paper analyzes the choices made by 194 women accessing postpartum clinic 
at Queen Elizabeth Central Hospital in Blantyre to accept or refuse VIA screening 
offered as part of routine care. Overall, more than two-thirds of the women had 
had two or more deliveries, and almost 90% reported currently enjoying good 
health, with extremely low levels of anxiety and depressive symptoms. A 
significant majority of women had traveled more than 30 minutes to attend 
clinic, and an equally large majority reported an intention to access family 
planning services as their motivation to attend PPC clinic.  
 
Contrary to what might be expected from the literature, neither lower education 




with refusing VIA. In addition, we hypothesized that factors like overall health, 
depressive and anxiety symptoms, and the intention to access family planning 
during the postpartum visit may be associated with refusal, but these were seen 
to be statistically unrelated. Relationship factors were significantly related to 
screening uptake. Married women were significantly more likely to accept 
screening, although this association attenuated in the multivariable model. The 
relationship between women’s sexual satisfaction and rates of acceptance 
remained significant even after adjusting for other variables. Women’s sexual 
satisfaction was unrelated to whether they had resumed sexual activity following 
their most recent delivery (76.9% who had resumed sex since delivery reported 
sexual satisfaction compared to 80.7% among women who had not, p=0.74), 
which might indicate a greater degree of autonomy within relationships. 
Additionally, it is possible that women reporting lower levels of satisfaction might 
wield relatively less autonomy, leading to lower rates of uptake of opportunistic 
screening offered during routine postpartum care.  
 
Screening for syphilis and HIV/AIDS are the most common diagnostic 
interventions offered to women during antenatal visits in LMICs. 5,66 Like HIV 
and syphilis, HPV transmission is linked to unprotected heterosexual contact and 
a positive VIA result elicited through screening during routine maternal care 
provides an opportunity for further evaluation and management. Co-location of 
VIA testing services with postpartum services, thus, follows an established 




cervical cancer screening is a logical candidate for integration with postpartum 
care. In our study, we saw that women attending postpartum clinic were 
significantly more likely to accept VIA screening (79.4% v/s 20.6%) than refuse, 
which has positive implications for integrating screening into routine postpartum 
care. Rates of refusal were not associated with time taken to reach clinic, 
employment status, parity, or the intention to access family planning services 
during the PPC visit. This indicates that women’s motivation to accept 
opportunistic VIA screening integrated with PPC might be unrelated to factors 
that are typically thought to influence their decision to access PPC. 
  
This study has some limitations that must be considered. The sample described 
in the study is restricted to women who accessed PPC at QECH in Blantyre.  
Thus, it is likely that the study sample is more health-compliant than the general 
population of women in Malawi, and that acceptance rates might be higher than 
what they would be in a community-based sample. A second limitation of the 
study is related to the sample sizes for some variables and the relatively smaller 
number of women who refused screening. Effective evaluation of a program 
designed to integrate VIA with PPC services would ideally capture a larger, more 
representative sample. Thirdly, as we do not have access to key information, 
including women’s financial status, reasons to accept or refuse screening, and 
other factors that may impact cervical cancer screening uptake, additional 
research is necessary to ensure that these findings hold for different settings. 




process indicators (time from onset of symptoms to screening, screening to 
confirmation, accessibility of healthcare facilities and quality of care) within the 
context of affordability of services. Finally, given the importance of relationship 
variables in determining acceptance of screening, future studies should 
investigate the role of these factors, including those of partners, in strategies 
designed to increase screening uptake.     
 
In spite of these limitations, we find strong evidence that it is feasible to integrate 
VIA screening with routine PPC visits in this setting in Malawi. Integration 
efforts would ideally institute staff training to make screening a routine 
component of PPC, as well as ensure appropriate referral and follow-up of 
positive cases (which was the prescribed protocol in this study as well). These 
results are particularly notable as Malawi has among the highest age-
standardized rates of cervical cancer in the world along with low rates of 
screening coverage. 45 The total fertility rate continues to be high in Malawi, and 
nearly 75% of all postpartum women report accessing PPC either at home (health 
visit) or at a facility in 2015. 67 Aggressive efforts to include VIA testing as a 
universal diagnostic option during PPC would contribute significantly to Malawi’s 
efforts to increase rates of early diagnosis and treatment of HPV infection More 
broadly, efforts to integrate VIA screening for early detection of cervical cancer 
into routine clinical settings is urgently needed in LMICs like Malawi that rely on 
overstretched health systems and inadequate funds to tackle high incidence rates 
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Chapter 5: Impact of Labia Minora Elongation 
(LME) on obstetric management and screening 
interventions among women attending antenatal 
or postpartum services in Queen Elizabeth 
Central Hospital, Blantyre 
 
5.1 Introduction and significance 
 
5.1.1 Background 
Labia minora elongation (LME) is a form of female genital modification practiced 
by multiple communities in Africa, including Malawi, Zimbabwe, Uganda, South 
Africa Mozambique and the DRC. 1-6 First described in western scientific 
literature as a morphological characteristic specific to the Khoi-San in South 
Africa, 7,8 LME has subsequently been established as a long-standing cultural 
practice in multiple communities across South Eastern Africa, either alone or 
part of a series of puberty initiation rites for pre-pubescent and adolescent girls. 9 
Manual stretching of the labia minora begins among girls aged 7-11 years within 
gender-segregated groups and may be accompanied with the use of special oils 
and powders prescribed by traditional healers. 10,11 LME is practiced among 
different ethnic communities in Malawi, including the Chewa, the country’s 




12,13 Specific rates of adherence to the ritual may vary in different geographical 
locations (for eg. Nyanja in Mozambique v/s Malawi), and might be influenced 
by factors like education and rural/ urban status. 14  
 
The WHO/ UNFPA/ UNICEF joint statement in 1997 classified “all procedures 
involving partial or total removal of the external female genitalia or other injury 
to the female genital organs for non-medical reasons” as female genital 
mutilation (FGM), categorized from 1-4 based on severity and type of practice. 
Categories 1-3 referred to clitoridectomy, labial excision and infibulation 
respectively, while category 4 was all unclassified practices including pricking, 
piercing, incising, cauterizing or pulling of the clitoris/ labia minora. 15,16 The 
revised statement in 2008, while acknowledging that LME had no long-term 
health consequences, justified it’s inclusion under FGM category 4, because it 
was “a social convention, and hence there is social pressure on young girls to 
modify their genitalia, and because it creates permanent genital changes”. 17 The 
2006 Malawi Human Rights Commission report, while simultaneously 
expressing concern about girls’ absence from families during initiation rituals 
and the potential for sexual abuse therein, nevertheless recognized the centrality 
of LME to marriage and fertility in Malawian society. 18 More recently, noting the 
vast difference in practice, implication and cultural significance between 
‘restrictive’ FGM procedures (cats. 1-3) and ‘expansive’ methods like LME as well 




researchers have questioned the utility of including LME within FGM category 4. 
19-21  
 
5.1.2 Sociodemographic and cultural implications of LME 
The practice of LME among different communities in Africa is almost always 
related to fertility and marriage, with some communities describing it as an 
essential pre-requisite for matrimony, and absence as grounds for abandonment 
or infidelity. 22-24 With a few reonal exceptions like in Lesotho, LME is linked to 
its role in enhancing sexual pleasure for men and women, as a signifier of 
fecundity in women, and for enlarging the introitus to promote easier 
childbearing. 4,10,25-27 In Malawi, labia minora elongation is seen as the first step 
in a series of puberty initiation rituals, often referred to as chinamwali, that 
follow a specific structure and are overseen by an older female instructor called 
the anamkungwi. Participation in the rites and fulfilment of the rituals is seen as 
integral to the process of transition from childhood to adulthood, and LME is 
central to beliefs surrounding sexual expression and fecundity. Puberty initiation 
rituals for girls may also include a period following the ceremonies characterized 
by social acceptance of sexually risky or promiscuous behavior, often with older 
men. Meanwhile, initiation rituals for boys often involve circumcision and a 
period of instruction and confinement culminating in a central event, which may 
be followed by a period of apparent social tolerance for sexually promiscuous 
behavior. 1,3,18,28 Although regular labial stretching is encouraged only up to the 




accompanied by the use of specific herbal oils, unguents, powders or poultices. 
2,9,11,29    
 
Labial elongation is currently practiced by multiple tribes in Malawi with 
different degrees of adherence, and it is widely recognized that the introduction 
of Christianity over the last two centuries has irrevocably changed traditional 
practices and imperatives among various groups, for eg the introduction of 
chilangizo, a Christianized alternative to traditional chinamwali ceremonies in 
the Baptist Synod of Malawi. 30,31   
 
The scientific literature surrounding labia minora elongation is fairly recent and 
almost exclusively qualitative. 32-35 Data from the Gender, Sexuality and Vaginal 
Practices (GSVP) study, a 2007 World Health Organization (WHO) - led multi-
country cross-sectional population-based survey study conducted in Mozambique 
and South Africa provides the few quantitative insights about the practice. 14,36 
Although there is considerable heterogeneity among specific practices, LME is 
often observed in matrilineal societies, and involves early initiation of girls in 
gender-segregated groups, often guided and supervised by older female relatives. 
28,32 Themes of enhanced confidence and social capital that accrue to girls who 
undertake LME and its associated rituals are almost ubiquitous in the literature. 
Furthermore, ritual instruction by the anamkungwi is also seen as an 
opportunity for education about social customs and cultural expectations. 




that LME is associated with being younger than 25 years; being a resident in rural 
areas; not having completed primary level education; and belonging to the 
Nyungwe ethno-linguistic group. Women who had LME were more likely to 
currently be in a relationship, have more than one partner, and have had history 
of recent sexual activity. 14 
 
In cases where LME is either universal or very rare among the local population, 
women who do not conform to the established norm may potentially face 
isolation and ostracism. 38 Interviews with immigrant women who had LME 
suggest that healthcare providers are often uninformed about the practice and 
mistakenly diagnose labial hypertrophy as a physiological artefact during clinical 
consultations. Women report a sense of enhanced scrutiny and judgement, 
especially when consulting clinicians unfamiliar with the practice or its cultural 
ramifications. This experience has been reported by immigrants in both 
European and African country contexts. 34,38 Within Malawi, discussions of LME 
have often been couched in the language of human rights violation of 
participating girls, and on the possible adverse consequences that may occur in 
situations where unsupervised sexual contact is encouraged among adolescents, 
especially after the initiation ceremony is complete, at 15 years of age. 18  
 
5.1.3 Health impact of LME 
The health risks associated with LME that have been explored in the literature 




application of herbal remedies, and the possibility of increased transmission of 
sexually transmitted infections (STIs) like HIV, especially in the context of 
superficial abrasions or trauma to the skin.39 Another area of research focuses on 
the implied consequences of puberty initiation rituals, of which LME might be a 
part. Specifically, the possibility of increased levels of promiscuity and risky 
sexual practices among adolescents who had undergone initiation rituals is 
hypothesized to be linked with increased STI transmission. 6,40 In spite of these 
different hypotheses, the review of literature provides little evidence of increased 
STI incidence among women practicing LME. 40-42 Psychological consequences 
arising from shame or ostracism are among the more serious health 
consequences of LME reported in the literature, although these seem to primarily 
be reported within the immigrant context. 34,38 
 
Our study represents the first attempt to describe sociodemographic background 
and healthcare access of women with LME in a large facility-based sample. Based 
on the research surrounding LME in Malawi, we anticipated that women who had 
LME who were attending maternal healthcare in Malawi might be largely similar 
to urban women in terms of health outcomes and care-seeking behavior, with 
possibility of difference in sociodemographic background, specifically education 
levels, marital status and fear of IPV. Noting the cultural explanations for LME as 
a means to enhancement of pleasure for both partners during sex, we expected 
some association with women’s reported sexual satisfaction. Again, considering 




partnerships, we expected an association with women’s reported fear of violence 
from their partners. Also considering the role of LME as a marker for female 
participation in larger social networks built on shared experiences and 
instruction, we hypothesized that it may influence rates of depression and 
anxiety. We also hypothesized that LME’s association with puberty initiation 
rituals and its prevalence among rural women with low levels of educational 
attainment may lead healthcare providers to assume different levels of health risk 
for these women. Specifically, clinicians might view women with LME as more 
promiscuous, or less informed about good clinical practices. They may be more 
likely to offer STI-related tests to women who have LME, or might be less likely 
to offer diagnostic and management interventions during antenatal and 
intrapartum care.     
 
5.2 Methods 
This study analyzes data from a pilot study on maternal morbidity in Malawi.  
Data were collected from women seeking antenatal and postpartum care in in 
Jamaica, Kenya and Malawi in 2015-16,  to assess and quantify morbidities. The 
study consisted of a questionnaire administered by trained investigators, a 
physical exam conducted by a clinician and a medical record review. The 
questionnaire recorded women’s reports of clinical symptomatology as well as 
maternal history and current health status, including functional assessment and 
mental health screening. 43-45 The questions were designed to assess female 




recent pregnancy. The questionnaire was administered by trained investigators 
who were newly graduated physicians from the College of Medicine, Blantyre. 
The physical exam, conducted either by a physician or nurse, consisted of a 
general obstetric exam followed by a pelvic inspection and internal exam. During 
the physical exam, attending clinicians recorded FGM status and specified the 
category (1-4).  Additional details of the study protocol are described elsewhere. 
43 Ethics approval was provided by WHO’s Research Ethics Review Committee 
(ERC) as well as the College of Medicine Research Support Center (COMREC), 
the ethics review and support board at the College of Medicine, Blantyre. 
 
5.2.1 Study site 
In Malawi, the Queen Elizabeth Central Hospital, Blantyre (QECH) was the study 
site. QECH is a 1120-bed public hospital serving the healthcare needs of Blantyre, 
Malawi’s second-biggest city, and of Southern Malawi. It is a tertiary care center, 
one of four ‘Central Hospitals’ as well as the only teaching hospital in Malawi 46. 
Due to the often-unreliable public healthcare services in rural areas of Southern 
Malawi, QECH caters to the primary care needs of the surrounding areas in 
addition to provision of tertiary care in all specialties. The Department of 
Obstetrics and Gynecology at the hospital has had between three and six 
specialist physicians, two to three registrars and three to five intern medical 
doctors at different times over the past decade. There are between two and four 





5.2.2 Study protocol 
Women attending either ANC clinic and more than 28 weeks pregnant, or 
attending PPC clinic at six weeks postpartum were invited to be part of the study. 
On agreeing to participate, women were screened to determine eligibility and 
were asked about their demographic background by the investigators. Eligible 
women who further consented to participating in the survey were administered 
the questionnaire, physical exam and record review. All data were collected on 
site by study investigators using hand-held devices, collated and transmitted to a 
central data repository where it was entered and cleaned. The physical exam was 
conducted following the interview by a clinician (physician or nurse) in a separate 
location at QECH, and the medical records were accessed from a review of 
National Health Passports in the possession of women participating in the study. 
Examining clinicians were not privy to the results of the questionnaire or the 
women’s responses. 49  
 
5.2.3 Study sample 
A total of 529 women (ANC=252, PPC=277) were approached to participate in 
the study and of these, 481 (ANC=239, PPC=242) consented to enroll in the 
study. 230 women from the ANC sample and 189 from the PPC sample (total N= 






5.2.4 Study variables 
The outcome of interest is the LME status of the woman, as reported by the 
clinician during the physical exam. We attempted to understand how LME status 
was related to woman’s sociodemographic characteristics, their health and 
wellbeing, and to access to healthcare services. To assess women’s 
sociodemographic background and access to healthcare service, we considered 
the woman’s age, education, marital status, parity (first pregnancy or delivery v/s 
all others) and time taken to reach the clinic. Education was assessed using both 
literacy and actual years of schooling, and the variable that was significantly 
associated was retained in the final model. The time taken to reach clinic is 
influenced by both distance and mode of transport, and may suggest levels of 
wealth - longer journey times may indicate the woman walked to QECH for her 
appointment or had access only to slower modes of public transportation. It may 
also be an indication of the distance from the Hospital, especially in the case of 
rural patients. 
 
We then analyzed the woman’s health and wellness, including reported fear of 
intimate partner violence (IPV), sexual satisfaction since onset of most recent 
pregnancy, self-reported health, and symptoms of depression or anxiety as 
recorded in the Generalized Anxiety Disorder (GAD7) or Personality Health 
Questionnaire (PHQ9) screening protocol. 50,51 As the incidence of clinical 
depression and anxiety was too low to be meaningfully considered in the analysis, 




depression and on the GAD7 scale for anxiety, and used this variable for analysis.  
In an attempt to determine signs of high risk pregnancy and postpartum 
morbidity recognizable to the clinician, we also explored the rates of anemia and 
pre-eclampsia as determined by clinical diagnosis, and abnormal signs on vaginal 
or vulvar exam during the physical exam. To assess whether health providers 
treated women with LME differently, we explored services women received after 
it was evident that the provider knew the woman’s LME status. Specifically, we 
considered the utilization of ultrasound services by currently pregnant women, 
cesarean section or use of instrumentation during most recent delivery and the 
offer of Visual Inspection with Acetic Acid (VIA) test for cervical cancer screening 
during the physical exam. In all three cases, the interventions would be offered to 
the patient by a clinician who was aware of their LME status. We expected that 
clinicians might be more likely to offer VIA screening to women with LME, 
probably influenced by notions about increased sexual exposure risk. Meanwhile, 
we expected rates of cesarean section and other interventions during delivery to 
be unchanged, in contrast to FGM categories 1-3, which demonstrate a clear 
association with higher rates of cesarean deliveries across Africa. 52 
 
5.2.5 Analysis plan 
We used t-tests and chi-square for significance testing to explore the bivariate 
associations between the sociodemographic characteristics of women who had 
(LME+) and had not undertaken LME (LME-). Next, using the same method, we 




Next considering only the theoretically important or statistically significant 
variables from the bivariate analysis, we created a series of multivariable logistic 
regression models that considered health outcomes and screening and 
management decisions associated with the woman’s LME status.  
 
5.3 Results 
Table 9 describes select sociodemographic, health and wellness and health access 
characteristics of women who have LME versus those who have not. Of the 481 
women attending ANC/ PPC clinic at QECH, 419 had a complete physical exam in 
which their LME status was recorded and routine screening tests were offered.  
 
54% of the sample had LME based on clinician examination. There were no 
significant differences between the women with and without LME in terms of age, 
marital status, parity or miscarriage rates. Women who had LME were 
significantly more likely to be illiterate or partially literate (12.4% v/s 6.2%, 
p=0.03), and were more likely to have taken more than half an hour to reach the 
clinic (74.3% v/s 62.2% p=0.007). In terms of their self-assessments, these 
women were neither more nor less likely to report satisfaction with their sex lives, 
report fear of IPV or report better or worse overall health (see Table 9). There was 
no difference in rates of anemia or pre-eclampsia diagnosed by the clinician, nor 
was there a difference in the rate of abnormal vaginal and vulvar signs on 
examination. Women who had undertaken LME were significantly less likely to 




depression (PHQ9) (23% vs. 33.7%, p=0.02). Women with LME attending 
postpartum clinic were also significantly less likely to report any depressive 
symptoms (23% vs. 33.7%, p=0.02) as compared to women without LME.   
 
When considering healthcare service provision, women with LME were 
significantly more likely to be offered VIA testing (77% vs. 66.1%, p=0.001). ANC 
clinic attendees who had LME were significantly less likely to have had an 
ultrasound during the current pregnancy (24.4% vs. 42.3%, p=0.04), and PPC 
clinic attendees with LME were far less likely to have had a cesarean section or 
any other form of instrumentation used during the most recent delivery (9.4% vs. 
22.0%, p=0.01). Of the 47 women who had had some form of intervention during 
the most recent delivery, 43 had had cesarean sections and the others had a 
forceps extraction during labor. 
 
Table 9: Sociodemographic and health characteristics of women accessing 
maternal healthcare services (ANC/ PPC) at QECH, Blantyre by LME (Labia 
Minora Elongation) status 
 
 












     Mean  












Literacy (%)    0.03 
Partially literate/ illiterate 6.2 (12) 12.4 (28) 9.6 (40)  
     Literate 93.8 (181) 87.6 (198) 90.5 (379)  
Education    0.24 




     Secondary school and higher 74.6 (144) 69.5 (157) 71.8 (301)  
Marital status    0.51 
     Single/ divorced/ separated 8.8 (17) 7.1 (16) 7.9 (33)  
     Married/cohabiting 91.2(176) 92.9 (210) 92.1 (386)  
Expresses fear of intimate 
partner violencea 
   0.17 
     No 95.3 (184) 91.6 (207) 93.3 (391)  
     Yes 4.7 (9) 8.4 (19) 6.7 (28)  
Time to reach clinic    0.007 
     <30 mins 37.8 (73) 25.7 (58) 31.3 (131)  
     >/= 30 mins 62.2 (120) 74.3 (168) 68.7 (288)  
Paritya    0.18 
     First pregnancy/ delivery 38.9 (75) 33.6 (76) 36.0 (151)  
     2 – 4 prev pregnancies  56.5 (109) 57.5 (130) 57.0 (151)  
     5+ prev pregnancies 4.7 (9) 8.9 (20) 6.9 (29)  
Woman’s health and wellness 
Self-reported health good/ 
very good 
   0.93 
     No  20.7 (40) 20.4 (46) 20.5 (86)  
     Yes 79.3 (153) 79.7 (180) 79.5 (333)  
Any anxiety symptoms 
(GAD-7) 
   0.06 
     No 51.8 (100) 61.1 (138) 56.8 (238)  
     Yes 48.2 (93) 38.9 (88) 43.2 (181)  
Any depressive symptoms 
(PHQ-9) 
   0.02 
     No 66.3 (128) 77.0 (174) 72.1 (302)  
     Yes 33.7 (65) 23.0 (52) 27.9 (117)  
Anemia (pallor + hemocue)    0.85 
     No 90.2 (174) 90.7 (205) 90.5 (379)  
     Yes 9.8 (19) 9.3 (21) 9.6 (40)  
Abnormal signs on vaginal 
exama  (N=409) 
   0.20 
     No 94.6 (176) 97.3 (217) 96.1 (393)  
     Yes 5.4 (10) 2.7 (6) 3.9 (16)  
Satisfied with sex life     0.78 
     No 29.5 (57) 28.3 (64) 28.9 (121)  
     Yes 70.5 (136) 71.7 (162) 71.1 (298)  




noted (Only ANC)a (n=230) 
     No 91.0 (101) 95.0 (113) 93.0 (214)  
     Yes 9.0 (10) 5.0 (6) 7.0 (16)  
Diagnostic and screening tests offered during ANC/ PPC care 
VIA screening offered    0.001 
     No 39.9 (77) 23.0 (52) 30.8 (129)  
     Yes 60.1 (116) 77.0 (174) 69.2 (290)  
Ultrasound during current 











     No 57.7 (64) 75.6 (90) 67.0 (154)  
     Yes  42.3 (47) 24.4 (29) 33.0 (76)  
Cesarean section/ 
instrumentation during 












     No 65.9 (54) 82.2 (88) 75.1 (142)  
     Yes 34.2 (28) 17.8 (19) 24.9 (47)  
a : Fischer’s exact test used due to small cell size 
 
Table 10 describes results of the adjusted multivariable logistic regression 
analyses of associations between LME status and women’s self-reported health as 
well as between LME status and treatment by the healthcare provider.  
 
Overall the results of multivariable logistic regression mirror the results from 
Table 9.  There was minimal attenuation after adjustment for important potential 
confounders.  After adjustment, women with LME were statistically significantly 
less like to report symptoms of depression (AOR=0.62, 95% CI: 0.40-0.95) or 
anxiety, although this association was only significant at the p<0.10 level 





Women who had LME were significantly more likely to be offered VIA screening 
by clinicians during the physical exam (AOR=2.15, 95% CI:1.40-3.29, p=0.001). 
Among ANC clinic attendees, women with LME were significantly less likely to be 
given an ultrasound (AOR=0.41, 95% CI:0.23-0.72, p=0.002) while PPC clinic 
attendees were less likely to have had instrumentation (including cesarean 
section) during the most recent delivery (AOR=0.49, 95% CI:0.24-1.00, p=0.06), 
even after controlling for parity, age, literacy, marital status and distance traveled 
to the clinic. 
 
Table 10: Health-related outcomes and provider treatment according to 
women’s LME status, adjusting for women’s sociodemographic characteristics 
among women attending ANC/ PPC care in QECH, Malawi  (n=419) 
 







Any depressive symptoms 0.59 (0.38-0.90)  
p=0.02 
0.65 (0.42-1.01)  
p=0.06 
Any anxiety symptoms 0.69 (0.46-1.01)  
p=0.06 
0.71 (0.50-1.11)  
p=0.15 
VIA offered 2.22 (1.45-3.39) 
p=0.0001 
2.06 (1.34-3.18)  
p=0.001 
Ultrasound during current 
pregnancyb 
0.44 (0.25-0.77)  
p=0.004 





0.42 (0.21-0.82)  
p=0.01 
0.50 (0.24-1.02)  
p=0.06 
a: Adjusted for age, literacy, marital status, parity, time traveled to the clinic  
b Only reported for women seeking antenatal care (n=230) 






This paper analyzes sociodemographic, wellness, and healthcare intervention 
data from 419 women accessing ANC/PPC care at the Queen Elizabeth Central 
Hospital, Blantyre in 2015, to determine the associations between cultural 
practices like LME and women’s wellness and reproductive healthcare access. 
LME is a clinical finding that is significant in and of itself, as well as through its 
association with a range of ethno-specific puberty initiation rituals that imply 
specific notions about personal behaviors or practices. Rural/urban differences 
and endogamous community practices might result in incomplete understanding 
of these customs across communities, extending sometimes to clinician attitudes.  
 
Although the cultural significance of LME is deeply entwined with its professed 
role in enhancing sexual pleasure for both partners, LME positive women in our 
sample did not report enhanced sexual satisfaction or reduced fear of IPV 
compared to their peers who did not undertake the practice. In general, we found 
that women who had LME had similar backgrounds to women who did not have 
LME, and enjoyed somewhat similar health status. However, they were more 
likely to be illiterate and rural residents, which may indicate a diminished 
capacity to negotiate with caregivers regarding healthcare interventions. They did 
not seem to exhibit an increased risk of adverse obstetric or physical health 
outcomes, however they were significantly less likely to report symptoms of 
anxiety or depression. Noting the voluntary nature of maternal healthcare access, 




suffer from anxiety and depression. This hypothesis is reflected in the low 
prevalence of mental health symptoms and generally high rates of good health 
reported by women in the study sample.       
 
The impact of LME was seen most strongly on clinical decision-making during 
maternal health provision, specifically the rates at which interventions like VIA 
screening for cervical cancer or elective procedures like ultrasound during 
antenatal care are offered to women Our analysis suggests that women who were 
LME positive were significantly more likely to be offered VIA screening during 
their ANC/ PPC visit. It is possible that clinicians might see LME as a marker for 
risky sexual behavior, and noting the well-established connection between 
multiple sexual partners and the risk of developing cervical cancer, 53 might 
choose to selectively offer VIA screening to these women. Conversely, women 
who were LME positive were significantly less likely to receive other 
interventions like ultrasound or cesarean sections during the antenatal and 
intrapartum periods. This is contrary to what has been observed in studies from 
multiple African countries of women exhibiting FGM categories 1-3 for whom 
cesarean rates seem to be significantly higher. 54 
 
The comparable sociodemographic and health profiles of women with LME and 
those without lead to inevitable questions about the wisdom of classifying LME 
within FGM category 4, and indeed, of the utility of a category that represents a 




evidence from this paper seems to point to the potential impact of LME on 
healthcare provider behavior, leading to differential rates of service provision. 
While it is difficult to speculate on the full range of preventive, diagnostic and 
curative interventions offered to a woman accessing ANC/ PPC care from this 
limited sample, the interventions we have chosen for analysis represent ones that 
were ostensibly ordered by a clinician who was aware of the patient’s LME status. 
The systematic differences between women who had LME and those who had not 
seems to indicate that healthcare providers may be treating these women 
differently, especially when assessing their eligibility for diagnostic, screening or 
management interventions. We do not know whether this translated into adverse 
health outcomes for women who had LME, but it is undeniable that differential 
rates of access to healthcare services to different populations impedes the goal of 
universal healthcare service provision.  
 
This study has some important limitations that must be kept in mind when 
considering the results of the analysis. Firstly, the absence of variables describing 
interventions that may have been offered to women by clinicians unaware of their 
LME status makes it difficult for us to authoritatively comment on the 
relationship between LME on inspection and clinical decision-making. Secondly, 
since the study did not measure care providers’ attitudes regarding their clinical 
practices, it is difficult to attribute the difference in rates of interventions offered 
to specific beliefs that may be held by the clinicians that are influencing their 




the variables that were collected in the MMMT study, allowing for possible 
confounding of results. Finally, the data are cross-sectional and reflect a selected 
sample of women who chose to come in for ANC and PPC.  Therefore, the data 
cannot be generalized to a non-facility sample and likely underrepresents women 
with adverse birth outcomes for the PPC sample. Again, since we do not know the 
full range of facilities and services accessed by the women for antenatal or 
postpartum care, it is difficult to draw  conclusions about differential provision of 
healthcare. In spite of these limitations, this paper represents the first attempt to 
analyze the healthcare experiences of women who have LME from within a 
facility-based sample. Further studies would analyze the reasons for the observed 
gap in offering these women routine services during healthcare, while also 
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Chapter 6: Discussion and Conclusions 
 
6.1 Discussion 
Integration of reproductive, maternal, newborn, child and adolescent health 
(RMNCAH) services follows a simple rationale – that although intended 
beneficiaries may access care at different ‘entry points’, their visit to healthcare 
facilities offers an opportunity to provide them the full range of appropriate 
screening, evaluation and management. 1 Employing a life cycle approach, 
healthcare providers can offer care that addresses both the patient’s current 
needs as well as anticipates their risk of future morbidity. 2 In low- and middle-
income countries (LMICs), visual inspection with acetic acid (VIA) testing for 
women accessing antenatal (ANC) or postpartum care (PPC) fulfils both these 
criteria by offering screening to women who are at risk of having contracted HPV 
but if infected, are likely to present with precancerous lesions that may be 
managed by passive management or early surgical intervention. VIA screening 
offers an accessible screening option that can be scaled up in resource-
constrained settings. Furthermore, LMICs tend to have high fertility and early 
childbearing along with a large proportion of screening-naïve women,  making 
the logic of integrating VIA screening with maternal health services all the more 
persuasive. 
 
Our study represents an attempt to understand the factors that might influence 




PPC clinics at a tertiary center in Malawi. By analyzing clinician and patient 
behavior as two distinct decision points, we attempt to understand potential 
barriers to VIA screening for women accessing maternal healthcare services. 
Since the data represent the experiences of women in a research study that 
required VIA screening of eligible women, our sample likely approximates the 
behavior of clinicians who might be part of an integrated program that mandated 
universal cervical cancer screening of ANC and PPC clinic attendees. 
 
Our results indicate that 4.4% of eligible women for VIA in ANC and 63.6% in 
PPC ultimately received VIA services. While this would imply that integration of 
VIA screening with PPC clinics at a tertiary center like Malawi’s Queen Elizabeth 
Central Hospital (QECH) is more efficient, ANC integration remains important 
considering the asymmetry in coverage of care. According to the 2015-16 
Demographic and Health Survey (DHS), only 42% of women who had given birth 
in the previous two years accessed PPC in Malawi, compared to 95% women who 
had at least one ANC visit with a skilled provider. In both cases, however, our 
assessment of VIA integration opportunities are likely over-estimated as a vast 
majority (72%) of pregnant women in Malawi access antenatal care from nurses 
or midwives who might not be currently capable of offering screening services. 3 
 
One of the primary advantages of healthcare integration is to reach out to a 
population with limited access to healthcare services. While the tertiary hospital 




provision among the most vulnerable group of women who do not seek services, 
our results suggest no evidence of social disparities in service provision of VIA 
once women enter the healthcare system, as women with less than secondary 
education were more likely to be offered services than higher educated women. 
We found differential provider practices for women with LME, a marker of 
ethnicity and cultural practice in Malawi. Noting the cultural behaviors 
associated with LME and puberty initiation rituals, the rural-urban divide, and 
the prevalence of endogamy within traditional communities likely to practice the 
ritual, 4-6 it is possible that clinicians might ascribe riskier sexual behaviors to 
these women, and offer them VIA screening at higher rates. Beyond these social 
determinants in VIA screening, our results suggest other forms of clinical barriers 
to VIA services, including pregnancy and abnormal vaginal discharge. Although 
VIA is not contraindicated in these circumstances, the exclusion of women with 
symptoms suggestive of sexually transmitted infections (STIs) from screening 
represents an added concern regarding those most at risk of harmful sequelae 
from HPV infection. 
 
To explore the impact of distinct socio-cultural practices on women’s access to 
obstetric screening, diagnostic and management options, we analyzed the effect 
of LME on VIA screening during the visit, ultrasound during current pregnancy 
and cesarean sections offered at most recent delivery. Women with LME were 
more likely to be illiterate and live in rural areas compared to women without 




with LME were less likely to report symptoms of depression compared to women 
without LME. Providers were significantly more likely to offer VIA screening to 
women with LME. Conversely, women with LME were significantly less likely to 
have been offered ultrasound services during their current pregnancy and less 
likely to have had a cesarean section during their most recent delivery. This may 
be a reflection of the differential access to tertiary services between rural and 
urban areas in Malawi, or may indicate a systematic exclusion of women with 
LME from diagnostic and management interventions during pregnancy and 
postpartum period. Although the reasons for this difference are not clear, it is 
possible that clinician attitudes about LME might impact appropriate offering of 
care. 
 
While service provision of VIA screening seems to favor women from less 
advantageous social backgrounds, women’s social status and personal attitudes 
still seem to be linked to the uptake of preventive care, as unmarried women and 
women reporting low sexual satisfaction were less likely to accept screening when 
VIA was integrated with PPC clinics. Women in less stable relationships may 
exercise lower autonomy over their healthcare decisions during routine primary 
care, prompting lower rates of screening uptake.  
 
6.2 Public Health Significance 
This study represents an exploration of the factors influencing uptake of cervical 




opportunistic VIA screening during maternal health services makes intuitive 
sense, the success of such a program depends on shared understanding by care 
providers and patients regarding the importance of universal screening coverage. 
Recognizing that care providers might exclude some kinds of women from 
screening and that women may be reluctant to undergo screening when offered, 
health information efforts should focus on emphasizing the goal of universal 
coverage and the benefits of early diagnosis and treatment. The experiences of 
integrating HIV/AIDS screening with ANC care could provide direction for the 
expansion of VIA screening access in LMICs. Offering VIA as an ‘opt out’ 
intervention during ANC and PPC, similar to current protocols for HIV and 
syphilis testing would likely impact screening coverage and improve early 
detection rates. At the same time, policymakers must be aware of the possibility 
of inadvertent exclusion of other women at risk of developing cervical cancer in 
an integrated maternal health – VIA screening program. The rollout of such an 
initiative must be accompanied by other integration strategies such as provision 




Integration of VIA screening with maternal healthcare provision must always be 
evaluated in the context of traditional community-based programs for cervical 
cancer screening. An evaluation of integrated program efficacy would ideally 




study, while providing one of the first looks at programs that integrate VIA 
screening with ANC and PPC clinics, also suggests some clear direction for future 
research in this area. Analysis of provider-patient interactions during VIA 
provision must extend to more generalizable primary care settings with variable 
clinician competence and differential access to follow up. Focused qualitative 
studies to understand women’s refusal of VIA screening in ANC clinics would 
help to identify barriers to care provision. Further investigation of healthcare 
providers’ attitudes regarding disease risk and VIA eligibility would inform 
training and clinical protocols. Understanding the barriers to provision and 
acceptance of VIA screening within integrated healthcare settings would allow us 
to create targeted programs that improve screening access and early detection 
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